Leber Optic Atrophy and Dystonia

Mendelian MONDO:0010772 Pathograph 13 Show in embeddings browser Leber Hereditary Optic Neuropathy Mitochondrial Disease

Leber optic atrophy and dystonia (LDYT; also called LHON-dystonia or LHOND; OMIM #500001) is an extremely rare mitochondrial DNA (mtDNA) disorder in which a complex I missense variant produces some combination of Leber hereditary optic neuropathy (LHON)-type bilateral optic atrophy and childhood- to adult-onset dystonia with bilateral basal ganglia (striatal) lesions. It is a distinct entity from isolated LHON: the overwhelming majority of molecularly confirmed cases carry the homoplasmic or heteroplasmic MT-ND6 m.14459G>A variant, which is essentially never found among patients with isolated classical LHON (caused by m.11778G>A, m.3460G>A, or m.14484T>C) or with isolated Leigh syndrome, indicating high tissue and phenotype specificity for this single amino-acid substitution (p.Ala72Val). A handful of other complex I loci (MT-ND1, MT-ND3, MT-ND4, and a second MT-ND6 site) have been linked to the same LDYT clinical picture in isolated families. Cybrid experiments assign a partial complex I biochemical defect directly to the m.14459G>A mtDNA lesion, altering the coenzyme Q-binding site of the enzyme and lowering NADH dehydrogenase-specific activity. Clinical expression is markedly heterogeneous even within a single maternal pedigree, ranging from asymptomatic carriage to isolated optic neuropathy, isolated pediatric-onset generalized dystonia with bilateral striatal necrosis, combined optic-atrophy-plus-dystonia, or (in homoplasmic infants) a fatal Leigh-like encephalomyopathy — a spectrum thought to reflect tissue-specific mutant load (heteroplasmy) and additional nuclear genetic modifiers rather than the primary mtDNA genotype alone. Because LDYT is maternally (mitochondrially) inherited, unlike autosomal or X-linked optic-atrophy-plus-dystonia phenocopies, targeted or whole mitochondrial genome sequencing is central to diagnosis whenever dystonia accompanies otherwise-unexplained bilateral optic neuropathy, or vice versa. There is no LDYT-specific approved therapy; management is extrapolated from general LHON visual care and standard symptomatic dystonia treatment (oral agents, botulinum toxin, and deep brain stimulation in refractory cases). LDYT must not be confused with Leber congenital amaurosis, an unrelated early-onset retinal dystrophy, nor with TIMM8A-related Mohr-Tranebjaerg (deafness-dystonia-optic neuronopathy) syndrome, an X-linked nuclear-encoded mitochondrial import disorder in which progressive sensorineural deafness, not maternal mtDNA transmission, is the presenting and defining feature.

Ask OpenScientist

Ask a research question about Leber Optic Atrophy and Dystonia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
16
Phenotypes
13
Pathograph
1
Genes
6
Medical Actions
2
Subtypes
1
References
1
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC
Mechanistic Nosology
mitochondrial disease
👪

Inheritance

1
Mitochondrial inheritance HP:0001427
LDYT is caused by pathogenic variants in the mitochondrial genome and is transmitted down the maternal line, most often the MT-ND6 m.14459G>A variant. Both homoplasmic and heteroplasmic transmission have been documented, and the same homoplasmic genotype can produce markedly different phenotypes (asymptomatic carriage, isolated dystonia, isolated optic neuropathy, or combined disease) even among siblings and other close maternal relatives within one pedigree, supporting a role for additional nuclear genetic modifiers. Heteroplasmic de novo occurrence has also been reported, in which the variant is undetectable in the unaffected mother's blood, urine sediment, and cultured fibroblasts.
Mitochondrial inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE
Show evidence (6 references)
PMID:8016139 SUPPORT Human Clinical
"A five-generation Hispanic family expressing maternally transmitted Leber hereditary optic neuropathy and/or early-onset dystonia associated with bilateral basal ganglia lesions was studied."
Original description establishes maternal transmission of the m.14459G>A variant across five generations.
PMID:8016139 SUPPORT Human Clinical
"Six maternal relatives in three generations were tested and were found to harbor the mutation, with one female affected with Leber hereditary optic neuropathy being heteroplasmic."
Documents both homoplasmic and heteroplasmic transmission of the variant within the same maternal pedigree.
PMID:14735585 SUPPORT Human Clinical
"supports the hypothesis that nuclear genes may play a role in modifying the clinical expression of mitochondrial disease"
Reports markedly variable clinical expression of the identical homoplasmic mtDNA genotype within one family, implicating nuclear modifiers.
+ 3 more references
◆

Subtypes

2
m.14459G>A (MT-ND6, p.Ala72Val)
MT-ND6 hgnc:7462 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in MT-ND6 (hgnc:7462). hgnc:7462 is a gene from the HUGO Gene Nomenclature Committee.
The canonical and by far the most frequently reported LDYT variant, accounting for the great majority of molecularly confirmed cases across Hispanic, Native American, Korean, Japanese, Chinese, and other pedigrees. It changes a moderately conserved alanine to a valine at ND6 residue 72, within the most evolutionarily conserved region of the protein, and has never been found in unaffected population reference panels or in patients with unrelated LHON or Leigh disease pedigrees lacking the LDYT phenotype.
Show evidence (2 references)
PMID:8016139 SUPPORT Human Clinical
"changed a moderately conserved alanine to a valine at NADH dehydrogenase subunit 6 (ND6) residue 72"
Identifies the specific amino-acid substitution caused by the m.14459G>A variant.
PMID:7654063 SUPPORT Human Clinical
"Patient groups that included individuals with Leigh's disease, dystonia plus complex neurodegeneration, and Leber's hereditary optic neuropathy did not harbor the MTND6*LDYT14459A mutation, suggesting that this mutation displays a high degree of tissue specificity"
Confirms the variant is specific to the LDYT phenotype and absent from unrelated LHON, Leigh disease, and dystonia cohorts.
Rare Allelic and Locus Heterogeneity (ND1, ND3, ND4, second ND6 site)
MT-ND1 hgnc:7455 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in MT-ND1 (hgnc:7455). hgnc:7455 is a gene from the HUGO Gene Nomenclature Committee. MT-ND3 hgnc:7458 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in MT-ND3 (hgnc:7458). hgnc:7458 is a gene from the HUGO Gene Nomenclature Committee. MT-ND4 hgnc:7459 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in MT-ND4 (hgnc:7459). hgnc:7459 is a gene from the HUGO Gene Nomenclature Committee.
A small number of unrelated families with an LDYT-like phenotype (optic atrophy, spastic dystonia, and basal ganglia lesions) instead carry a different complex I mtDNA variant: a second MT-ND6 site (m.14596T>A), MT-ND4 m.11696A>G, or MT-ND1 m.3697G>A; a further variant, MT-ND3 m.10197G>A, has been reported as a rare primary LHON mutation. Double mutations (e.g., co-occurring MT-ND4 and MT-ND6 common LHON variants) have also produced an LDYT-like optic-neuropathy-plus-dystonia picture, sometimes with additional multisystem features such as transverse myelitis, illustrating that the clinical syndrome has meaningful locus and allelic heterogeneity beyond the single dominant m.14459G>A variant.
Show evidence (2 references)
PMID:31776719 SUPPORT Human Clinical
"at least five single mutations have been pathogenically associated with LDYT: MT-ND6 m.14459G>A and m.14596T>A, MT-ND4 m.11696A>G, MT-ND1 m.3697G>A and MT-ND3 m.10197G>A"
Enumerates the rare non-m.14459G>A complex I loci reported to cause the LDYT clinical picture.
PMID:31776719 SUPPORT Human Clinical
"The clinical characteristics of LDYT are: optic atrophy, spastic dystonia, basal ganglia lesions, and nearly absent complex I activity."
Confirms these alternate loci reproduce the same core LDYT clinical triad, supporting locus heterogeneity within a single clinical entity.
⚙

Pathophysiology

6
MT-ND6 m.14459G>A Missense Mutation
The initiating lesion is most often a homoplasmic or heteroplasmic G-to-A transition at mtDNA position 14459 within MT-ND6, encoding NADH:ubiquinone oxidoreductase core subunit 6 of respiratory-chain complex I. The substitution changes a moderately conserved alanine to a valine at ND6 residue 72 (p.Ala72Val), within the most evolutionarily conserved region of the protein. Rarer alternate lesions at other complex I loci (MT-ND1, MT-ND3, MT-ND4, or a second MT-ND6 site) produce a mechanistically analogous complex I defect in individual families. Because mtDNA is present in every cell, the lesion itself is systemic; the resulting disease phenotype is not.
MT-ND6 hgnc:7462 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves MT-ND6 (hgnc:7462). hgnc:7462 is a gene from the HUGO Gene Nomenclature Committee. MT-ND1 hgnc:7455 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves MT-ND1 (hgnc:7455). hgnc:7455 is a gene from the HUGO Gene Nomenclature Committee. MT-ND4 hgnc:7459 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves MT-ND4 (hgnc:7459). hgnc:7459 is a gene from the HUGO Gene Nomenclature Committee.
NADH dehydrogenase (ubiquinone) activity GO:0008137 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased NADH dehydrogenase (ubiquinone) activity (GO:0008137). GO:0008137 is a molecular function from the Gene Ontology. ↓ DECREASED
mitochondrial inner membrane GO:0005743 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves mitochondrial inner membrane (GO:0005743). GO:0005743 is a cellular component from the Gene Ontology.
Downstream
Complex I Assembly and Coenzyme Q-Binding Site Defect The p.Ala72Val substitution impairs assembly and/or catalytic function of the complex I holoenzyme, most directly documented through altered binding of the coenzyme Q substrate analog.
Show evidence (2 references)
PMID:8016139 SUPPORT Human Clinical
"a G-to-A transition at nucleotide pair (np) 14459, changed a moderately conserved alanine to a valine at NADH dehydrogenase subunit 6 (ND6) residue 72"
Identifies the founding molecular lesion and its amino-acid consequence.
PMID:7654063 SUPPORT Human Clinical
"A novel point mutation in the ND6 subunit of complex I at position 14,459 of the mitochondrial DNA (MTND6*LDY T14459A) was identified as a candidate mutation for the highly tissue-specific disease. Leber's hereditary optic neuropathy plus dystonia."
Independently confirms the ND6 np 14459 mutation as the candidate cause of the LDYT phenotype in additional pedigrees.
Complex I Assembly and Coenzyme Q-Binding Site Defect
Transmitochondrial cybrid experiments — in which patient Epstein-Barr-virus-transformed lymphoblasts were enucleated and fused to a mtDNA-deficient recipient cell line — assign a partial complex I biochemical defect directly to the ND6 m.14459G>A mutation, separating the mtDNA effect from nuclear genetic background. Submitochondrial particles from patient cell lines showed a 60% reduction in complex I-specific activity relative to controls, with normal activity for complexes II+III, III, and IV; cybrid lines carrying the mutation showed a smaller but still significant 39% reduction. Kinetic analysis found a reduced Vmax with unchanged Km, and specific activity was inhibited by increasing concentrations of a reduced coenzyme Q analog (decylubiquinol), suggesting the mutation alters the coenzyme Q-binding site of the enzyme rather than abolishing catalysis outright.
NADH dehydrogenase (ubiquinone) activity GO:0008137 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased NADH dehydrogenase (ubiquinone) activity (GO:0008137). GO:0008137 is a molecular function from the Gene Ontology. ↓ DECREASED
mitochondrial inner membrane GO:0005743 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves mitochondrial inner membrane (GO:0005743). GO:0005743 is a cellular component from the Gene Ontology.
Downstream
Oxidative Phosphorylation Deficiency and Redox Imbalance Reduced NADH dehydrogenase activity impairs electron transfer from NADH to ubiquinone, lowering the coupled ATP-generating capacity of oxidative phosphorylation and predisposing to redox imbalance.
Show evidence (3 references)
PMID:8622678 SUPPORT In Vitro
"Enzymologic analysis of mitochondrial NADH dehydrogenase (complex I) with submitochondrial particles isolated from Epstein-Barr virus-transformed lymphoblasts revealed a 60% reduction (P < 0.005) of complex I-specific activity in patient cell lines compared with controls, with no differences in..."
Directly measures the complex I-specific biochemical defect in patient-derived cell lines.
PMID:8622678 SUPPORT In Vitro
"Cybrids harboring the np 14459 mutation exhibited a 39% reduction (p < 0.02) in complex I-specific activity relative to wild-type cybrid lines but normal activity for the other complexes."
Assigns the complex I defect directly to the mtDNA mutation using cybrids, isolating it from nuclear background effects.
PMID:8622678 SUPPORT In Vitro
"specific activity was inhibited by increasing concentrations of the reduced coenzyme Q analog decylubiquinol. These observations suggest that the np 14459 mutation may alter the coenzyme Q-binding site of complex I."
Provides the specific biochemical hypothesis for how the mutation impairs complex I function.
Oxidative Phosphorylation Deficiency and Redox Imbalance
The combination of reduced electron flux through complex I and altered coenzyme Q utilization lowers ATP output and predisposes to a chronic bioenergetic deficit. Cerebral and systemic lactic acidosis, documented on brain MR spectroscopy and blood/CSF chemistry in affected pedigrees, is the clinical correlate of this impaired oxidative metabolism.
oxidative phosphorylation GO:0006119 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased oxidative phosphorylation (GO:0006119). GO:0006119 is a biological process from the Gene Ontology. ↓ DECREASED mitochondrial electron transport, NADH to ubiquinone GO:0006120 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased mitochondrial electron transport, NADH to ubiquinone (GO:0006120). GO:0006120 is a biological process from the Gene Ontology. ↓ DECREASED
mitochondrial inner membrane GO:0005743 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves mitochondrial inner membrane (GO:0005743). GO:0005743 is a cellular component from the Gene Ontology.
Downstream
Tissue-Selective Neuronal Bioenergetic Vulnerability A generalized, systemic bioenergetic deficit is converted into a tissue-restricted disease by the disproportionate vulnerability of specific long-axon, high-energy-demand neuronal populations.
Show evidence (1 reference)
PMID:14735585 SUPPORT Human Clinical
"MRI of the brain demonstrated bilateral, symmetric basal ganglia lucencies associated with cerebral and systemic lactic acidosis."
Documents the clinical redox/metabolic correlate (lactic acidosis) accompanying the basal ganglia lesions.
Tissue-Selective Neuronal Bioenergetic Vulnerability
Two neuronal populations with disproportionately high, spatially distributed ATP demand are selectively vulnerable to the complex I defect: retinal ganglion cells, whose long, partly unmyelinated intraretinal axons (as in classical LHON) impose an especially high energy burden, and striatal projection neurons of the basal ganglia. Why these two populations specifically decompensate, while most other tissues remain clinically unaffected, is not fully resolved, but tissue- and cell-type-specific mutant load (heteroplasmy) is the best-supported explanation: a Japanese series found homoplasmic mutant load producing infantile dystonia while a heteroplasmic variant of the same mutation produced later-onset truncal ataxia and parkinsonism, and involvement of the visual pathway is generally a later event than dystonia in patients who develop both.
Retinal ganglion cell CL:0000740 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Retinal ganglion cell (CL:0000740). CL:0000740 is a cell type from the Cell Ontology. Medium spiny neuron CL:1001474 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Medium spiny neuron (CL:1001474). CL:1001474 is a cell type from the Cell Ontology.
response to oxidative stress GO:0006979 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to oxidative stress (GO:0006979). GO:0006979 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Retinal Ganglion Cell Degeneration and Optic Atrophy In individuals whose bioenergetic threshold is crossed in the visual pathway, retinal ganglion cells degenerate, producing optic atrophy and central vision loss.
Striatal Neurodegeneration and Bilateral Basal Ganglia Necrosis In individuals whose bioenergetic threshold is crossed in the striatum, medium spiny projection neurons of the caudate and putamen degenerate, producing bilateral basal ganglia lesions ranging from MRI/CT lucencies to frank necrosis.
Show evidence (2 references)
PMID:40190371 SUPPORT Human Clinical
"This was seen in a Japanese series with homoplasmic mutations resulting in infantile dystonia and heteroplasmic variant showing a later juvenile onset truncal ataxia and parkinsonism."
Supports tissue- and load-dependent selective vulnerability as the basis for divergent phenotypes from the same mtDNA variant.
PMID:40190371 SUPPORT Human Clinical
"The involvement of visual pathways in 14459G>A-mutated patients is generally a later event in contrast to dystonia that develops in the early childhood."
Documents the differential temporal vulnerability of the two affected neuronal populations.
Retinal Ganglion Cell Degeneration and Optic Atrophy
As in classical LHON, retinal ganglion cell loss produces progressive optic nerve atrophy and permanent central visual impairment. Optic atrophy and increased T2 signal on optic-nerve/orbital MRI are the imaging correlates, and central scotoma with dyschromatopsia are the characteristic visual-field and color-vision consequences when this branch of the disease is expressed.
Retinal ganglion cell CL:0000740 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Retinal ganglion cell (CL:0000740). CL:0000740 is a cell type from the Cell Ontology.
neuron apoptotic process GO:0051402 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neuron apoptotic process (GO:0051402). GO:0051402 is a biological process from the Gene Ontology. ↑ INCREASED
retina UBERON:0000966 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in retina (UBERON:0000966). UBERON:0000966 is an anatomical location from the Uberon multi-species anatomy ontology. optic nerve UBERON:0000941 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in optic nerve, annotated with cranial nerve II (UBERON:0000941). UBERON:0000941 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Optic Atrophy Retinal ganglion cell and axonal loss culminates in the clinical endpoint of bilateral optic atrophy and permanent central visual impairment, on the same visual pathway affected in classical LHON.
Show evidence (1 reference)
PMID:32045392 SUPPORT Human Clinical
"Brain MRI T2 short tau inversion recovery sequences demonstrated optic atrophy in 62.5% (10/16); increased T2 signal in the optic nerve was found in 38% (6/16) of patients."
Quantifies optic atrophy and optic-nerve T2 signal change in a rare-primary-mutation LHON cohort that includes the m.14459G>A LHON-plus-dystonia patient.
Striatal Neurodegeneration and Bilateral Basal Ganglia Necrosis
Bilateral, usually symmetric degeneration of the caudate nucleus and putamen produces the neuroimaging hallmark of LDYT: bilateral basal ganglia lucencies on CT or MRI, which can progress to frank necrosis. This lesion is the anatomical substrate for the disease's dystonic and associated pyramidal/bulbar features.
Medium spiny neuron CL:1001474 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Medium spiny neuron (CL:1001474). CL:1001474 is a cell type from the Cell Ontology.
putamen UBERON:0001874 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in putamen (UBERON:0001874). UBERON:0001874 is an anatomical location from the Uberon multi-species anatomy ontology. caudate nucleus UBERON:0001873 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in caudate nucleus (UBERON:0001873). UBERON:0001873 is an anatomical location from the Uberon multi-species anatomy ontology. basal ganglion UBERON:0002420 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in basal ganglion (UBERON:0002420). UBERON:0002420 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Generalized Dystonia Striatal projection neuron loss disrupts basal ganglia-thalamocortical motor circuits, producing progressive generalized dystonia, often accompanied by spasticity, dysarthria, and gait impairment.
Show evidence (2 references)
PMID:20052369 SUPPORT Human Clinical
"we describe a Korean family presenting with pediatric-onset, progressive, generalized dystonia with bilateral striatal necrosis and the homoplasmic G14459A mutation in the mitochondrial ND6 gene"
Documents bilateral striatal necrosis as the neuroimaging correlate of the disease in a homoplasmic m.14459G>A family.
PMID:28503604 SUPPORT Human Clinical
"showing bilateral magnetic resonance imaging lesions in nucleus pallidus and putamen"
Documents the specific basal ganglia nuclei (globus pallidus and putamen) affected in two further m.14459G>A cases.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Leber Optic Atrophy and Dystonia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

16
Eye 4
Visual Loss HP:0000572 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual loss (HP:0000572). HP:0000572 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:40190371 SUPPORT Human Clinical
"presented to the Neurology Department with sudden onset blurring of vision on waking up, which initially affected the right eye but rapidly also involved the left"
Documents acute-onset, initially unilateral then rapidly bilateral visual loss in a genetically confirmed m.14459G>A LDYT patient.
PMID:32045392 SUPPORT Human Clinical
"worst Snellen best-corrected visual acuity ≤0.1 (worse than 20/200)"
Documents severe visual acuity loss in a rare-primary-mutation LHON cohort that includes the single m.14459G>A LHON-plus-dystonia patient; recorded PARTIAL and deliberately without a frequency qualifier because this is a cohort-level aggregate across several rare mtDNA variants and, per the source's own framing, must not be read as an m.14459G>A/LDYT-specific frequency.
Optic Atrophy HP:0000648 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Optic atrophy (HP:0000648), qualified as course progressive. HP:0000648 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:32045392 SUPPORT Human Clinical
"The patient with LHON plus dystonia demonstrated optic atrophy and increased T2 signal in basal ganglia."
Documents optic atrophy co-occurring with basal ganglia disease in the single m.14459G>A LHON-plus-dystonia case in this cohort.
PMID:40190371 SUPPORT Human Clinical
"dilated fundoscopy showed bilateral temporal pallor, with the optic nerve heads being worse on the right"
Documents bilateral optic disc pallor (early optic atrophy) developing 24 years after childhood-onset dystonia in this patient.
Central Scotoma HP:0000603 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Central scotoma (HP:0000603). HP:0000603 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40190371 SUPPORT Human Clinical
"Goldman visual field examination showed central scotomas"
Documents central scotoma on formal visual field testing in a genetically confirmed m.14459G>A LDYT patient.
Ptosis OCCASIONAL HP:0000508 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ptosis (HP:0000508). HP:0000508 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31776719 SUPPORT Human Clinical
"he had a history of primary ocular symptoms beginning in childhood with bilateral ptosis and poor vision of the right eye"
Documents bilateral ptosis as an early ocular manifestation in a patient with LHON-plus dystonia due to double complex I mtDNA mutations.
Musculoskeletal 2
Spasticity HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20052369 SUPPORT Human Clinical
"spasticity in both lower extremity, spinal scoliosis, dystonic hands, and generalized hypotonia, retropulsion, with mild mental retar"
Documents lower-extremity spasticity co-occurring with dystonia and other neurological features in this pedigree.
Joint Contractures Flexion contracture HP:0001371 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint contractures, annotated with Flexion contracture (HP:0001371). HP:0001371 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20052369 SUPPORT Human Clinical
"showed severe dysarthria, contractures of both ankle and wrist, both knee contractures"
Documents fixed contractures of multiple joints as a long-term consequence of dystonia.
Nervous System 5
Bilateral Striatal Necrosis Basal ganglia necrosis HP:0012128 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Basal ganglia necrosis (HP:0012128). HP:0012128 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20052369 SUPPORT Human Clinical
"Brain MRI showed the presence of bilateral symmetric tissue losses in both the putamen and caudate nucleus"
Documents bilateral necrosis (tissue loss) of the putamen and caudate nucleus on brain MRI.
Dysarthria HP:0001260 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysarthria (HP:0001260), qualified as course progressive. HP:0001260 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:20052369 SUPPORT Human Clinical
"The proband and younger brother (III-14) was unable to communicate by phone because of severe dysarthria."
Documents severe, functionally limiting dysarthria in affected family members.
Gait Disturbance HP:0001288 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gait disturbance (HP:0001288), qualified as course progressive. HP:0001288 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:20052369 SUPPORT Human Clinical
"they developed unilateral distal dystonic posture and gait disturbances"
Documents gait disturbance as an early presenting sign of the disease.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31776719 SUPPORT Human Clinical
"optic neuropathy, ptosis, ataxia, dystonia, dysarthria, and recurrent extensive transverse myelitis"
Documents ataxia as part of the multisystem LHON-plus-dystonia presentation.
PMID:20301353 SUPPORT Human Clinical
"Neurologic abnormalities such as postural tremor, peripheral neuropathy, nonspecific myopathy, and movement disorders have been reported to be more common in individuals with LHON than in the general population."
GeneReviews documents movement disorders, which include ataxia, as enriched in LHON generally; recorded PARTIAL because this background statement is about LHON as a whole rather than the LDYT/m.14459G>A pedigrees specifically.
Mild Intellectual Disability OCCASIONAL HP:0001256 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mild intellectual disability (HP:0001256). HP:0001256 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20052369 SUPPORT Human Clinical
"generalized hypotonia, retropulsion, with mild mental retar"
Documents mild mental retardation (intellectual disability) as a feature in some affected family members.
PMID:28503604 SUPPORT Human Clinical
"Both children have reached their teenage years, and they are intellectually active, despite their motor problems."
Notes that cognition is well preserved and intellectually active in other reported cases, illustrating the variability of this feature; recorded as PARTIAL because it documents the absence of cognitive impairment rather than its presence.
Growth 1
Short Stature OCCASIONAL HP:0004322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20052369 SUPPORT Human Clinical
"Pediatric onset disease associated with the G14459A mutation is characterized by dystonia, short stature, bulbar and corticospinal tract dysfunction, and basal ganglia degeneration on brain magnetic resonance imaging (MRI)."
Names short stature as a component of the characteristic pediatric-onset m.14459G>A phenotype.
Other 4
Generalized Dystonia HP:0007325 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized dystonia (HP:0007325), qualified as course progressive. HP:0007325 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:7654063 SUPPORT Human Clinical
"a single individual presented with childhood-onset generalized dystonia and bilateral basal ganglia lesions"
Documents childhood-onset generalized dystonia with bilateral basal ganglia lesions as a core LDYT presentation.
PMID:20052369 SUPPORT Human Clinical
"The proband had shown dysarthria, progressive generalized dystonia, and spasticity at 5 yr."
Documents progressive generalized dystonia with onset at age 5 in a homoplasmic m.14459G>A family.
Bilateral Basal Ganglia Lesions HP:0007146 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bilateral basal ganglia lesions (HP:0007146). HP:0007146 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:8016139 SUPPORT Human Clinical
"early-onset dystonia associated with bilateral basal ganglia lesions was studied"
Documents bilateral basal ganglia lesions as a core, co-occurring finding with early-onset dystonia in the original pedigree.
PMID:28503604 SUPPORT Human Clinical
"showing bilateral magnetic resonance imaging lesions in nucleus pallidus and putamen"
Documents specific bilateral basal ganglia nuclei affected on MRI.
Dyschromatopsia HP:0007641 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dyschromatopsia (HP:0007641). HP:0007641 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40190371 SUPPORT Human Clinical
"she reported significant red and green discoloration of her vision"
Documents red-green color vision disturbance during the acute visual episode in a genetically confirmed m.14459G>A LDYT patient.
Fatal Leigh-like Encephalomyopathy in Homoplasmic Infants VERY_RARE
Show evidence (1 reference)
PMID:28503604 SUPPORT Human Clinical
"the same mutation caused severe Leigh syndrome in 2 siblings who died at 6 years and 10 months, and the first had dystonic posturing in addition to extreme hypotonia, spasticity, and seizures."
Documents fatal Leigh syndrome, with dystonic posturing, hypotonia, spasticity, and seizures, in siblings homoplasmic for the m.14459G>A variant, the most severe end of the LDYT phenotypic spectrum.
🧬

Genetic Associations

1
MT-ND6 (The homoplasmic or heteroplasmic m.14459G>A variant (p.Ala72Val) is the predominant molecular cause of LDYT, identified in maternal pedigrees of diverse ancestry and, in a minority of cases, as a de novo heteroplasmic occurrence. )
Gene: MT-ND6 hgnc:7462 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MT-ND6 (hgnc:7462). hgnc:7462 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:8016139 SUPPORT Human Clinical
"the np 14459 G-to-A missense mutation is specific to this family, alters a moderately conserved amino acid in a complex I gene, is a unique mtDNA variant in Native American haplogroup D, and is heteroplasmic, suggesting that it is the disease-causing mutation"
Original genetic evidence identifying the m.14459G>A MT-ND6 variant as the disease-causing mutation.
💊

Medical Actions

6
Idebenone
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: idebenone CHEBI:31687 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses idebenone (CHEBI:31687). CHEBI:31687 is a therapeutic agent from Chemical Entities of Biological Interest.
A short-chain quinone that can bypass a defective complex I by accepting electrons via NQO1 and delivering them downstream to complex III. It is authorised for LHON generally (EMA, exceptional circumstances) but its benefit has not been separately established for the LDYT/dystonia phenotype specifically.
Show evidence (1 reference)
PMID:20301353 SUPPORT Human Clinical
"Idebenone (Raxone®) has been approved for the treatment of LHON by the European Medicines Agency under exceptional circumstances."
GeneReviews documents EMA approval and some visual benefit for idebenone in LHON generally; recorded as PARTIAL because the benefit is established for LHON broadly, not specifically for the LDYT/dystonia phenotype modeled in this entry.
Oral Dystonia Pharmacotherapy Trial
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Empiric oral dystonia agents (levodopa, baclofen, tizanidine) have been trialed in LDYT; non-response has been documented in at least one genetically confirmed case, consistent with LDYT being a non-dopa-responsive dystonia. This contrasts with the symptomatic relief obtained from botulinum toxin and deep brain stimulation in other reported cases.
Show evidence (1 reference)
PMID:40190371 SUPPORT Human Clinical
"Her generalized dystonia was non-responsive to L-dopa, baclofen, and tizanidine treatment trials."
Documents non-response to standard oral dystonia agents in a genetically confirmed m.14459G>A LDYT patient, the negative but clinically informative finding behind the description's non-dopa-responsive characterization.
Visual Aids and Occupational Rehabilitation
Action: RehabilitationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Rehabilitation (NCIT:C15315). NCIT:C15315 is a clinical intervention from the NCI Thesaurus. NCIT:C15315
General LHON supportive care (visual aids, occupational rehabilitation, and registration with relevant social services) is the standard management for the optic-neuropathy branch of LDYT, extrapolated from LHON overall since no LDYT-specific supportive-care study exists.
Show evidence (1 reference)
PMID:20301353 SUPPORT Human Clinical
"Management of affected individuals remains mostly supportive, and includes provision of visual aids, occupational rehabilitation, and registration with the relevant social services."
GeneReviews' general LHON supportive-care recommendation; recorded PARTIAL because it is written for LHON overall rather than demonstrated specifically in LDYT.
Multidisciplinary Management of Extraocular Neurologic Features
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
A multidisciplinary approach (neurology, physical/occupational therapy, and cardiology) is recommended for the extraocular neurologic features of LHON-plus disease, which is directly on point for LDYT since its defining feature is extraocular (dystonia, ataxia, peripheral neuropathy). Cardiology referral is additionally recommended for any LHON-causing mtDNA variant carrier found to have pre-excitation on EKG.
Show evidence (2 references)
PMID:20301353 SUPPORT Human Clinical
"A multidisciplinary approach for those affected individuals with extraocular neurologic features (ataxia, peripheral neuropathy, nonspecific myopathy, and movement disorders) should be considered to minimize the functional consequences of these complications."
GeneReviews recommends multidisciplinary management specifically for the extraocular neurologic features that define LHON-plus disease, directly applicable to LDYT's dystonia/ataxia presentation.
PMID:20301353 SUPPORT Human Clinical
"Referral to a cardiologist for individuals with pre-excitation syndrome on EKG is recommended; treatment for symptomatic individuals is per standard practice."
GeneReviews' general LHON recommendation for cardiology referral on EKG pre-excitation; recorded PARTIAL because it is written for LHON overall rather than demonstrated specifically in LDYT pedigrees.
Botulinum Toxin Injection
Action: botulinum toxin therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is botulinum toxin therapy (NCIT:C157775). NCIT:C157775 is a clinical intervention from the NCI Thesaurus. Ontology label: Botulinum Toxin Therapy NCIT:C157775
Used for symptomatic relief of focal or segmental dystonic posturing, for example of the arm, in LDYT patients with generalized dystonia.
Show evidence (1 reference)
PMID:28503604 SUPPORT Human Clinical
"he has received significant symptomatic relief with Botox injections"
Documents symptomatic benefit from botulinum toxin injection for dystonic limb posturing in a genetically confirmed m.14459G>A case.
Globus Pallidus Internus Deep Brain Stimulation
Action: deep brain stimulationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is deep brain stimulation (NCIT:C21024). NCIT:C21024 is a clinical intervention from the NCI Thesaurus. Ontology label: Deep Brain Stimulation NCIT:C21024
Considered for medically refractory generalized dystonia in LDYT, extrapolated from its established use in other genetic and idiopathic dystonias; no LDYT-specific response rate has been established.
Show evidence (1 reference)
PMID:40190371 SUPPORT Human Clinical
"she was implanted with a Bilateral Globus Pallidus Internal Deep Brain Stimulator (DBS) at age 15 years"
Documents bilateral globus pallidus internus DBS used to manage refractory generalized dystonia in a genetically confirmed m.14459G>A LDYT patient.
🌍

Environmental Factors

3
Tobacco Smoking
exposure to tobacco smoking ECTO:6000029 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to tobacco smoking (ECTO:6000029). ECTO:6000029 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
General LHON avoidance counselling (no smoking) is extrapolated to LDYT carriers because the underlying complex I lesion and bioenergetic threshold logic are shared with classical LHON, even though smoking-penetrance data have not been separately generated for m.14459G>A pedigrees.
Show evidence (1 reference)
PMID:20301353 SUPPORT Human Clinical
"strongly advised not to smoke and to moderate alcohol intake, avoiding binge-drinking episodes"
GeneReviews' avoidance recommendation for carriers of any LHON-causing mtDNA variant; extrapolated to LDYT rather than separately demonstrated.
Mechanism Target:
EXACERBATES Tissue-Selective Neuronal Bioenergetic Vulnerability — Mitochondrial-toxic exposures are thought to further load a bioenergetic system already compromised by the primary complex I lesion, pushing vulnerable retinal ganglion cells and striatal neurons past a functional threshold. This is the same penetrance-gating logic established for classical LHON; the quantitative smoking-penetrance study underlying it (93% clinical penetrance in male smokers) was conducted in classical LHON pedigrees, not specifically in m.14459G>A LDYT families, so the link is extrapolated rather than independently demonstrated for this entity.
Show evidence (1 reference)
PMID:20301353 SUPPORT Human Clinical
"Individuals in whom a LHON-causing mtDNA variant has been identified should be strongly advised not to smoke and to moderate alcohol intake, avoiding binge-drinking episodes."
GeneReviews advises carriers of any LHON-causing mtDNA variant, the class that includes MT-ND6 m.14459G>A, to avoid smoking; recorded PARTIAL because the underlying penetrance evidence was generated in classical LHON cohorts rather than in LDYT pedigrees specifically.
Heavy Alcohol Intake
exposure to alcohol consumption ECTO:0001082 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to alcohol consumption (ECTO:0001082). ECTO:0001082 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Moderation of alcohol intake and avoidance of binge drinking is extrapolated general LHON counselling; no LDYT-specific quantitative alcohol-penetrance data were identified.
Show evidence (1 reference)
PMID:20301353 SUPPORT Human Clinical
"to moderate alcohol intake, avoiding binge-drinking episodes"
GeneReviews' avoidance recommendation for carriers of any LHON-causing mtDNA variant; extrapolated to LDYT rather than separately demonstrated.
Mechanism Target:
EXACERBATES Tissue-Selective Neuronal Bioenergetic Vulnerability — Alcohol is grouped with the same bioenergetic-threshold logic as smoking. As with smoking, the recommendation to moderate intake is GeneReviews' general LHON guidance applied here; no LDYT-specific alcohol-penetrance study was identified.
Show evidence (1 reference)
PMID:20301353 SUPPORT Human Clinical
"to moderate alcohol intake, avoiding binge-drinking episodes"
GeneReviews advises moderating alcohol intake for carriers of any LHON-causing mtDNA variant; extrapolated to LDYT rather than separately demonstrated.
Mitochondrial-Toxic Drug Exposure
exposure to mitochondrial NADH:ubiquinone reductase inhibitor ECTO:9001785 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to mitochondrial NADH:ubiquinone reductase inhibitor (ECTO:9001785). ECTO:9001785 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
GeneReviews recommends carriers of any LHON-causing mtDNA variant avoid head trauma, industrial toxins, and drugs with mitochondrial toxic effects generally; the complex I-specific ECTO term used here is a reasonable mechanistic fit for a disease already defined by a complex I lesion, but no LDYT- or m.14459G>A-specific study of this exposure class was identified.
Show evidence (1 reference)
PMID:20301353 SUPPORT Human Clinical
"It would be reasonable to avoid exposure to other putative environmental triggers for visual loss, such as head trauma, industrial toxins, and drugs with mitochondrial toxic effects."
GeneReviews' general recommendation to avoid mitochondrial-toxic drugs and other environmental triggers for carriers of any LHON-causing mtDNA variant.
Mechanism Target:
EXACERBATES Tissue-Selective Neuronal Bioenergetic Vulnerability — A drug that itself inhibits complex I NADH:ubiquinone oxidoreductase activity would add to, rather than merely coexist with, the primary m.14459G>A lesion's own effect on the same enzyme, plausibly accelerating the same bioenergetic-threshold logic as smoking and alcohol. This is a mechanistic extrapolation from GeneReviews' general avoidance advice rather than an LDYT-specific dosing or exposure study.
Show evidence (1 reference)
PMID:20301353 SUPPORT Human Clinical
"drugs with mitochondrial toxic effects"
GeneReviews recommends avoiding drugs with mitochondrial toxic effects for carriers of any LHON-causing mtDNA variant; extrapolated to LDYT and to the complex I-specific ECTO term rather than separately demonstrated.
🔬

Biochemical Markers

1
Lactate (INCREASED)
Context: Cerebral and/or systemic lactic acidosis has been documented alongside the bilateral basal ganglia lesions in some LDYT pedigrees, consistent with the underlying complex I oxidative phosphorylation deficiency, but is not universally present or required for diagnosis.
Pathograph Readouts
Readout Of Oxidative Phosphorylation Deficiency and Redox Imbalance Positive Diagnostic
Elevated lactate/pyruvate is the clinical biochemical correlate of the underlying complex I-driven oxidative phosphorylation deficit.
Show evidence (1 reference)
PMID:31776719 SUPPORT Human Clinical
"Venous lactate and pyruvate were elevated (4mM, with normal values 0.5–2.2 mM, and 0.23 mM, with normal values 0.03–0.15 mM, respectively)."
Quantifies elevated venous lactate and pyruvate in a genetically confirmed complex I mtDNA LHON-plus-dystonia patient.
Show evidence (1 reference)
PMID:14735585 SUPPORT Human Clinical
"MRI of the brain demonstrated bilateral, symmetric basal ganglia lucencies associated with cerebral and systemic lactic acidosis."
Documents cerebral and systemic lactic acidosis co-occurring with the basal ganglia lesions in an m.14459G>A pedigree.
🔬

Diagnosis

2
Targeted then Complete mtDNA Sequencing with Heteroplasmy Quantification
Diagnosis rests on identifying a complex I mtDNA variant, most often m.14459G>A in MT-ND6, in a proband with optic neuropathy and/or dystonia plus bilateral basal ganglia lesions. Because mutant load can differ substantially between tissues, testing more than one accessible tissue (blood, urine sediment, buccal mucosa, or skin fibroblasts) is important when a low-level or discordant heteroplasmy result is suspected, rather than relying on blood alone.
Show evidence (2 references)
PMID:28503604 SUPPORT Human Clinical
"The heteroplasmy level in the urinary sediment was 91% and in buccal mucosa 89% in patient 1, but in patient 2 the heteroplasmy level was 59% in fibroblasts."
Documents markedly tissue-dependent heteroplasmy levels for the m.14459G>A variant across urine sediment, buccal mucosa, and fibroblasts, supporting multi-tissue testing.
PMID:28503604 SUPPORT Human Clinical
"Total DNA was extracted from skeletal muscle, skin fibroblasts, blood, urinary sediment, and buccal smears"
Documents the panel of accessible tissues sampled for mtDNA heteroplasmy testing in genetically confirmed cases.
Targeted mtDNA Testing for the Three Common LHON Variants First
Because the three common LHON mtDNA variants account for the great majority of molecularly diagnosed LHON, targeted testing for these should be performed first even when dystonia or basal ganglia disease accompanies the optic neuropathy; only when this is negative does testing proceed to complete mtDNA sequencing that can detect m.14459G>A and other rare complex I loci.
Show evidence (2 references)
PMID:36317462 SUPPORT Human Clinical
"92% (184/199) carrying one of the three main pathogenic variants of mitochondrial DNA (m.11778G>A, 66.5%; m.3460G>A, 15% and m.14484T>C, 11%)"
Quantifies that the three common LHON variants explain the great majority of molecularly diagnosed LHON, supporting them as the appropriate first-line targeted test before broader mtDNA sequencing that would detect rarer LDYT-associated loci.
PMID:20301353 SUPPORT Human Clinical
"The diagnosis of LHON is established in a proband with a consistent clinical history and/or one of three common mitochondrial DNA (mtDNA) pathogenic variants identified on molecular genetic testing."
GeneReviews defines the general LHON diagnostic basis around the three common variants; recorded PARTIAL because LDYT commonly requires testing beyond those three, which is exactly the nuance captured by this entry's first diagnosis entry.
📊

Prevalence

1
Worldwide
Cases In Literature Rare
No population-based prevalence or incidence estimate has been published for LDYT specifically; it is known only from isolated case reports and small maternal pedigrees (fewer than a dozen published families/case series across Hispanic/Native American, Korean, Japanese, Chinese, and other ancestries), distinct from the population-based prevalence figures available for classical LHON (see the sibling Leber_Hereditary_Optic_ Neuropathy.yaml entry).
Show evidence (1 reference)
PMID:31776719 SUPPORT Human Clinical
"The association of LHON with spastic dystonia (LDYT) is also rare (OMIM#500001)"
States directly that LDYT is a rare presentation, distinct from classical LHON.
{ }

Source YAML

click to show 
name: Leber Optic Atrophy and Dystonia
creation_date: "2026-08-18T04:02:08Z"
category: Mendelian
disease_term:
  preferred_term: Leber optic atrophy and dystonia
  term:
    id: MONDO:0010772
    label: Leber optic atrophy and dystonia
description: >
  Leber optic atrophy and dystonia (LDYT; also called LHON-dystonia or LHOND;
  OMIM #500001) is an extremely rare mitochondrial DNA (mtDNA) disorder in
  which a complex I missense variant produces some combination of Leber
  hereditary optic neuropathy (LHON)-type bilateral optic atrophy and
  childhood- to adult-onset dystonia with bilateral basal ganglia (striatal)
  lesions. It is a distinct entity from isolated LHON: the overwhelming
  majority of molecularly confirmed cases carry the homoplasmic or
  heteroplasmic MT-ND6 m.14459G>A variant, which is essentially never found
  among patients with isolated classical LHON (caused by m.11778G>A, m.3460G>A,
  or m.14484T>C) or with isolated Leigh syndrome, indicating high tissue and
  phenotype specificity for this single amino-acid substitution (p.Ala72Val).
  A handful of other complex I loci (MT-ND1, MT-ND3, MT-ND4, and a second
  MT-ND6 site) have been linked to the same LDYT clinical picture in isolated
  families. Cybrid experiments assign a partial complex I biochemical defect
  directly to the m.14459G>A mtDNA lesion, altering the coenzyme Q-binding
  site of the enzyme and lowering NADH dehydrogenase-specific activity.
  Clinical expression is markedly heterogeneous even within a single
  maternal pedigree, ranging from asymptomatic carriage to isolated optic
  neuropathy, isolated pediatric-onset generalized dystonia with bilateral
  striatal necrosis, combined optic-atrophy-plus-dystonia, or (in homoplasmic
  infants) a fatal Leigh-like encephalomyopathy — a spectrum thought to
  reflect tissue-specific mutant load (heteroplasmy) and additional nuclear
  genetic modifiers rather than the primary mtDNA genotype alone. Because
  LDYT is maternally (mitochondrially) inherited, unlike autosomal or
  X-linked optic-atrophy-plus-dystonia phenocopies, targeted or whole
  mitochondrial genome sequencing is central to diagnosis whenever dystonia
  accompanies otherwise-unexplained bilateral optic neuropathy, or vice versa.
  There is no LDYT-specific approved therapy; management is extrapolated from
  general LHON visual care and standard symptomatic dystonia treatment
  (oral agents, botulinum toxin, and deep brain stimulation in refractory
  cases). LDYT must not be confused with Leber congenital amaurosis, an
  unrelated early-onset retinal dystrophy, nor with TIMM8A-related
  Mohr-Tranebjaerg (deafness-dystonia-optic neuronopathy) syndrome, an
  X-linked nuclear-encoded mitochondrial import disorder in which
  progressive sensorineural deafness, not maternal mtDNA transmission, is the
  presenting and defining feature.
synonyms:
- LDYT
- LHON-dystonia
- LHOND
- Leber's hereditary optic neuropathy with dystonia
- LHON and dystonia
- dystonia, familial, with visual failure and striatal lucencies
parents:
- Leber Hereditary Optic Neuropathy
- Mitochondrial Disease

references:
- reference: PMID:20301353
  title: "Leber Hereditary Optic Neuropathy."
  tags:
  - GeneReviews

inheritance:
- name: Mitochondrial inheritance
  description: >
    LDYT is caused by pathogenic variants in the mitochondrial genome and is
    transmitted down the maternal line, most often the MT-ND6 m.14459G>A
    variant. Both homoplasmic and heteroplasmic transmission have been
    documented, and the same homoplasmic genotype can produce markedly
    different phenotypes (asymptomatic carriage, isolated dystonia, isolated
    optic neuropathy, or combined disease) even among siblings and other
    close maternal relatives within one pedigree, supporting a role for
    additional nuclear genetic modifiers. Heteroplasmic de novo occurrence
    has also been reported, in which the variant is undetectable in the
    unaffected mother's blood, urine sediment, and cultured fibroblasts.
  inheritance_term:
    preferred_term: Mitochondrial inheritance
    term:
      id: HP:0001427
      label: Mitochondrial inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  evidence:
  - reference: PMID:8016139
    reference_title: "A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A five-generation Hispanic family expressing maternally transmitted Leber hereditary optic neuropathy and/or early-onset dystonia associated with bilateral basal ganglia lesions was studied."
    explanation: Original description establishes maternal transmission of the m.14459G>A variant across five generations.
  - reference: PMID:8016139
    reference_title: "A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Six maternal relatives in three generations were tested and were found to harbor the mutation, with one female affected with Leber hereditary optic neuropathy being heteroplasmic."
    explanation: Documents both homoplasmic and heteroplasmic transmission of the variant within the same maternal pedigree.
  - reference: PMID:14735585
    reference_title: "Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "supports the hypothesis that nuclear genes may play a role in modifying the clinical expression of mitochondrial disease"
    explanation: Reports markedly variable clinical expression of the identical homoplasmic mtDNA genotype within one family, implicating nuclear modifiers.
  - reference: PMID:28503604
    reference_title: "A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report heteroplasmic 14459G>A mutations in 2 unrelated children with nonmaternally inherited generalized dystonia"
    explanation: Documents de novo (non-maternally-inherited) heteroplasmic occurrence of the variant, an exception to strict maternal transmission.
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the presence of homoplasmic G14459A mutation in asymptomatic individuals"
    explanation: Demonstrates incomplete penetrance, with homoplasmic carriers who remain clinically asymptomatic.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A female (affected or unaffected) with a primary LHON-causing mtDNA variant transmits the variant to all of her offspring."
    explanation: GeneReviews states the maternal-transmission rule that governs any primary LHON-causing mtDNA variant, the class that includes the MT-ND6 m.14459G>A LDYT variant.

has_subtypes:
- name: MT-ND6 m.14459G>A
  display_name: "m.14459G>A (MT-ND6, p.Ala72Val)"
  description: >
    The canonical and by far the most frequently reported LDYT variant,
    accounting for the great majority of molecularly confirmed cases across
    Hispanic, Native American, Korean, Japanese, Chinese, and other
    pedigrees. It changes a moderately conserved alanine to a valine at ND6
    residue 72, within the most evolutionarily conserved region of the
    protein, and has never been found in unaffected population reference
    panels or in patients with unrelated LHON or Leigh disease pedigrees
    lacking the LDYT phenotype.
  genes:
  - preferred_term: MT-ND6
    term:
      id: hgnc:7462
      label: MT-ND6
  evidence:
  - reference: PMID:8016139
    reference_title: "A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "changed a moderately conserved alanine to a valine at NADH dehydrogenase subunit 6 (ND6) residue 72"
    explanation: Identifies the specific amino-acid substitution caused by the m.14459G>A variant.
  - reference: PMID:7654063
    reference_title: "Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient groups that included individuals with Leigh's disease, dystonia plus complex neurodegeneration, and Leber's hereditary optic neuropathy did not harbor the MTND6*LDYT14459A mutation, suggesting that this mutation displays a high degree of tissue specificity"
    explanation: Confirms the variant is specific to the LDYT phenotype and absent from unrelated LHON, Leigh disease, and dystonia cohorts.
- name: Other Complex I Loci
  display_name: "Rare Allelic and Locus Heterogeneity (ND1, ND3, ND4, second ND6 site)"
  description: >
    A small number of unrelated families with an LDYT-like phenotype
    (optic atrophy, spastic dystonia, and basal ganglia lesions) instead
    carry a different complex I mtDNA variant: a second MT-ND6 site
    (m.14596T>A), MT-ND4 m.11696A>G, or MT-ND1 m.3697G>A; a further variant,
    MT-ND3 m.10197G>A, has been reported as a rare primary LHON mutation.
    Double mutations (e.g., co-occurring MT-ND4 and MT-ND6 common LHON
    variants) have also produced an LDYT-like optic-neuropathy-plus-dystonia
    picture, sometimes with additional multisystem features such as
    transverse myelitis, illustrating that the clinical syndrome has
    meaningful locus and allelic heterogeneity beyond the single dominant
    m.14459G>A variant.
  genes:
  - preferred_term: MT-ND1
    term:
      id: hgnc:7455
      label: MT-ND1
  - preferred_term: MT-ND3
    term:
      id: hgnc:7458
      label: MT-ND3
  - preferred_term: MT-ND4
    term:
      id: hgnc:7459
      label: MT-ND4
  evidence:
  - reference: PMID:31776719
    reference_title: "Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "at least five single mutations have been pathogenically associated with LDYT: MT-ND6 m.14459G>A and m.14596T>A, MT-ND4 m.11696A>G, MT-ND1 m.3697G>A and MT-ND3 m.10197G>A"
    explanation: Enumerates the rare non-m.14459G>A complex I loci reported to cause the LDYT clinical picture.
  - reference: PMID:31776719
    reference_title: "Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical characteristics of LDYT are: optic atrophy, spastic dystonia, basal ganglia lesions, and nearly absent complex I activity."
    explanation: Confirms these alternate loci reproduce the same core LDYT clinical triad, supporting locus heterogeneity within a single clinical entity.

phenotypes:
- category: Neurological
  name: Generalized Dystonia
  description: >
    Progressive, often severe generalized dystonia is the defining
    extraocular manifestation of LDYT, frequently starting distally
    (foot, hand) and becoming generalized over months to years. Onset is
    typically before age 5 years in pediatric-onset pedigrees, though
    adult-onset cases occur.
  phenotype_term:
    preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:7654063
    reference_title: "Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a single individual presented with childhood-onset generalized dystonia and bilateral basal ganglia lesions"
    explanation: Documents childhood-onset generalized dystonia with bilateral basal ganglia lesions as a core LDYT presentation.
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband had shown dysarthria, progressive generalized dystonia, and spasticity at 5 yr."
    explanation: Documents progressive generalized dystonia with onset at age 5 in a homoplasmic m.14459G>A family.
- category: Neurological
  name: Bilateral Basal Ganglia Lesions
  description: >
    Bilateral, usually symmetric lucencies or necrosis of the caudate
    nucleus and putamen on CT or MRI, a near-constant neuroradiologic
    finding when the striatal branch of the disease is expressed, whether
    or not optic neuropathy is also present.
  phenotype_term:
    preferred_term: Bilateral basal ganglia lesions
    term:
      id: HP:0007146
      label: Bilateral basal ganglia lesions
  diagnostic: true
  evidence:
  - reference: PMID:8016139
    reference_title: "A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "early-onset dystonia associated with bilateral basal ganglia lesions was studied"
    explanation: Documents bilateral basal ganglia lesions as a core, co-occurring finding with early-onset dystonia in the original pedigree.
  - reference: PMID:28503604
    reference_title: "A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showing bilateral magnetic resonance imaging lesions in nucleus pallidus and putamen"
    explanation: Documents specific bilateral basal ganglia nuclei affected on MRI.
- category: Neurological
  name: Bilateral Striatal Necrosis
  description: >
    In severely affected pedigrees, the basal ganglia lesions progress to
    frank bilateral tissue necrosis of the putamen and caudate nucleus,
    rather than remaining as isolated signal change alone.
  phenotype_term:
    preferred_term: Basal ganglia necrosis
    term:
      id: HP:0012128
      label: Basal ganglia necrosis
  evidence:
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain MRI showed the presence of bilateral symmetric tissue losses in both the putamen and caudate nucleus"
    explanation: Documents bilateral necrosis (tissue loss) of the putamen and caudate nucleus on brain MRI.
- category: Neurological
  name: Dysarthria
  description: >
    Progressive dysarthria, sometimes severe enough to preclude
    intelligible speech, accompanies generalized dystonia in pediatric-onset
    pedigrees.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband and younger brother (III-14) was unable to communicate by phone because of severe dysarthria."
    explanation: Documents severe, functionally limiting dysarthria in affected family members.
- category: Neurological
  name: Spasticity
  description: >
    Lower-extremity spasticity commonly accompanies dystonia in
    pediatric-onset LDYT and contributes to gait impairment and eventual
    wheelchair dependence.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "spasticity in both lower extremity, spinal scoliosis, dystonic hands, and generalized hypotonia, retropulsion, with mild mental retar"
    explanation: Documents lower-extremity spasticity co-occurring with dystonia and other neurological features in this pedigree.
- category: Neurological
  name: Joint Contractures
  description: >
    Chronic dystonic posturing and spasticity lead to fixed joint
    contractures of the ankles, wrists, and knees in long-standing,
    severely affected individuals.
  phenotype_term:
    preferred_term: Joint contractures
    term:
      id: HP:0001371
      label: Flexion contracture
  evidence:
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showed severe dysarthria, contractures of both ankle and wrist, both knee contractures"
    explanation: Documents fixed contractures of multiple joints as a long-term consequence of dystonia.
- category: Neurological
  name: Gait Disturbance
  description: >
    Progressive gait disturbance, often beginning with distal dystonic
    posturing of the foot, is typically the earliest motor sign and can
    progress to wheelchair dependence.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "they developed unilateral distal dystonic posture and gait disturbances"
    explanation: Documents gait disturbance as an early presenting sign of the disease.
- category: Neurological
  name: Ataxia
  description: >
    Ataxia has been reported as part of the broader LDYT/LHON-plus movement
    disorder spectrum, particularly in adult-onset or multisystem cases.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:31776719
    reference_title: "Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "optic neuropathy, ptosis, ataxia, dystonia, dysarthria, and recurrent extensive transverse myelitis"
    explanation: Documents ataxia as part of the multisystem LHON-plus-dystonia presentation.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic abnormalities such as postural tremor, peripheral neuropathy, nonspecific myopathy, and movement disorders have been reported to be more common in individuals with LHON than in the general population."
    explanation: GeneReviews documents movement disorders, which include ataxia, as enriched in LHON generally; recorded PARTIAL because this background statement is about LHON as a whole rather than the LDYT/m.14459G>A pedigrees specifically.
- category: Neurological
  name: Mild Intellectual Disability
  description: >
    Mild intellectual impairment has been reported in some severely
    affected pedigree members, though cognition is well preserved and even
    academically successful in many other reported cases.
  phenotype_term:
    preferred_term: Mild intellectual disability
    term:
      id: HP:0001256
      label: Mild intellectual disability
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "generalized hypotonia, retropulsion, with mild mental retar"
    explanation: Documents mild mental retardation (intellectual disability) as a feature in some affected family members.
  - reference: PMID:28503604
    reference_title: "A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both children have reached their teenage years, and they are intellectually active, despite their motor problems."
    explanation: Notes that cognition is well preserved and intellectually active in other reported cases, illustrating the variability of this feature; recorded as PARTIAL because it documents the absence of cognitive impairment rather than its presence.
- category: Ophthalmological
  name: Visual Loss
  description: >
    Loss of vision, typically acute or subacute in onset and initially
    unilateral before rapidly involving the fellow eye, is the presenting
    ophthalmic complaint when the visual-pathway branch of LDYT is
    expressed, preceding the chronic optic atrophy that follows it.
  phenotype_term:
    preferred_term: Visual loss
    term:
      id: HP:0000572
      label: Visual loss
  evidence:
  - reference: PMID:40190371
    reference_title: "Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presented to the Neurology Department with sudden onset blurring of vision on waking up, which initially affected the right eye but rapidly also involved the left"
    explanation: Documents acute-onset, initially unilateral then rapidly bilateral visual loss in a genetically confirmed m.14459G>A LDYT patient.
  - reference: PMID:32045392
    reference_title: "Clinical Features of Chinese Sporadic Leber Hereditary Optic Neuropathy Caused by Rare Primary mtDNA Mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "worst Snellen best-corrected visual acuity \u22640.1 (worse than 20/200)"
    explanation: Documents severe visual acuity loss in a rare-primary-mutation LHON cohort that includes the single m.14459G>A LHON-plus-dystonia patient; recorded PARTIAL and deliberately without a frequency qualifier because this is a cohort-level aggregate across several rare mtDNA variants and, per the source's own framing, must not be read as an m.14459G>A/LDYT-specific frequency.
- category: Ophthalmological
  name: Optic Atrophy
  description: >
    Bilateral optic atrophy, the LHON-type component of LDYT, occurs when
    the visual pathway branch of the disease is expressed; it can precede,
    follow by years, or co-occur with the dystonia.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:32045392
    reference_title: "Clinical Features of Chinese Sporadic Leber Hereditary Optic Neuropathy Caused by Rare Primary mtDNA Mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient with LHON plus dystonia demonstrated optic atrophy and increased T2 signal in basal ganglia."
    explanation: Documents optic atrophy co-occurring with basal ganglia disease in the single m.14459G>A LHON-plus-dystonia case in this cohort.
  - reference: PMID:40190371
    reference_title: "Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dilated fundoscopy showed bilateral temporal pallor, with the optic nerve heads being worse on the right"
    explanation: Documents bilateral optic disc pallor (early optic atrophy) developing 24 years after childhood-onset dystonia in this patient.
- category: Ophthalmological
  name: Central Scotoma
  description: >
    A dense central visual field defect, the visual-field correlate of
    optic atrophy when the ocular branch of the disease is expressed.
  phenotype_term:
    preferred_term: Central scotoma
    term:
      id: HP:0000603
      label: Central scotoma
  evidence:
  - reference: PMID:40190371
    reference_title: "Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Goldman visual field examination showed central scotomas"
    explanation: Documents central scotoma on formal visual field testing in a genetically confirmed m.14459G>A LDYT patient.
- category: Ophthalmological
  name: Dyschromatopsia
  description: >
    Impaired color discrimination accompanies the acute/subacute visual
    loss when the ocular branch of the disease is expressed, mirroring
    classical LHON.
  phenotype_term:
    preferred_term: Dyschromatopsia
    term:
      id: HP:0007641
      label: Dyschromatopsia
  evidence:
  - reference: PMID:40190371
    reference_title: "Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "she reported significant red and green discoloration of her vision"
    explanation: Documents red-green color vision disturbance during the acute visual episode in a genetically confirmed m.14459G>A LDYT patient.
- category: Ophthalmological
  name: Ptosis
  description: >
    Bilateral ptosis has been reported as part of the broader
    LHON-plus-dystonia phenotype in some affected individuals, though it is
    not a defining or universal feature.
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:31776719
    reference_title: "Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he had a history of primary ocular symptoms beginning in childhood with bilateral ptosis and poor vision of the right eye"
    explanation: Documents bilateral ptosis as an early ocular manifestation in a patient with LHON-plus dystonia due to double complex I mtDNA mutations.
- category: Musculoskeletal
  name: Short Stature
  description: >
    Short stature has been reported as part of the pediatric-onset
    G14459A phenotype alongside dystonia and bulbar/corticospinal
    dysfunction.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pediatric onset disease associated with the G14459A mutation is characterized by dystonia, short stature, bulbar and corticospinal tract dysfunction, and basal ganglia degeneration on brain magnetic resonance imaging (MRI)."
    explanation: Names short stature as a component of the characteristic pediatric-onset m.14459G>A phenotype.
- category: Neurological
  name: Fatal Leigh-like Encephalomyopathy in Homoplasmic Infants
  description: >
    At the most severe end of the phenotypic spectrum, virtually homoplasmic
    mutant load of the same m.14459G>A variant has caused fatal infantile
    Leigh syndrome (subacute necrotizing encephalomyelopathy) rather than
    the childhood-onset dystonia or adult-onset optic neuropathy typical of
    less heavily loaded carriers. No specific HPO term for Leigh syndrome
    exists as a phenotype (it is modeled in HPO/MONDO as a disease, not a
    finding), so this entry is deliberately left without a bound ontology
    term rather than mapped to an imprecise parent.
  phenotype_term:
    preferred_term: Fatal Leigh-like encephalomyopathy
  frequency: VERY_RARE
  evidence:
  - reference: PMID:28503604
    reference_title: "A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the same mutation caused severe Leigh syndrome in 2 siblings who died at 6 years and 10 months, and the first had dystonic posturing in addition to extreme hypotonia, spasticity, and seizures."
    explanation: Documents fatal Leigh syndrome, with dystonic posturing, hypotonia, spasticity, and seizures, in siblings homoplasmic for the m.14459G>A variant, the most severe end of the LDYT phenotypic spectrum.

pathophysiology:
- name: MT-ND6 m.14459G>A Missense Mutation
  biological_scale: MOLECULAR
  description: >
    The initiating lesion is most often a homoplasmic or heteroplasmic
    G-to-A transition at mtDNA position 14459 within MT-ND6, encoding
    NADH:ubiquinone oxidoreductase core subunit 6 of respiratory-chain
    complex I. The substitution changes a moderately conserved alanine to a
    valine at ND6 residue 72 (p.Ala72Val), within the most evolutionarily
    conserved region of the protein. Rarer alternate lesions at other
    complex I loci (MT-ND1, MT-ND3, MT-ND4, or a second MT-ND6 site) produce
    a mechanistically analogous complex I defect in individual families.
    Because mtDNA is present in every cell, the lesion itself is systemic;
    the resulting disease phenotype is not.
  genes:
  - preferred_term: MT-ND6
    term:
      id: hgnc:7462
      label: MT-ND6
  - preferred_term: MT-ND1
    term:
      id: hgnc:7455
      label: MT-ND1
  - preferred_term: MT-ND4
    term:
      id: hgnc:7459
      label: MT-ND4
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  molecular_functions:
  - preferred_term: NADH dehydrogenase (ubiquinone) activity
    term:
      id: GO:0008137
      label: NADH dehydrogenase (ubiquinone) activity
    modifier: DECREASED
  evidence:
  - reference: PMID:8016139
    reference_title: "A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a G-to-A transition at nucleotide pair (np) 14459, changed a moderately conserved alanine to a valine at NADH dehydrogenase subunit 6 (ND6) residue 72"
    explanation: Identifies the founding molecular lesion and its amino-acid consequence.
  - reference: PMID:7654063
    reference_title: "Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A novel point mutation in the ND6 subunit of complex I at position 14,459 of the mitochondrial DNA (MTND6*LDY T14459A) was identified as a candidate mutation for the highly tissue-specific disease. Leber's hereditary optic neuropathy plus dystonia."
    explanation: Independently confirms the ND6 np 14459 mutation as the candidate cause of the LDYT phenotype in additional pedigrees.
  downstream:
  - target: Complex I Assembly and Coenzyme Q-Binding Site Defect
    description: >
      The p.Ala72Val substitution impairs assembly and/or catalytic function
      of the complex I holoenzyme, most directly documented through altered
      binding of the coenzyme Q substrate analog.
    evidence:
    - reference: PMID:8622678
      reference_title: "Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "This ND6 np 14459 mutation changes a moderately conserved alanine to a valine at amino acid position 72 of the ND6 protein."
      explanation: Confirms the specific amino acid substitution is the mutation being assigned a biochemical complex I defect in this study.

- name: Complex I Assembly and Coenzyme Q-Binding Site Defect
  biological_scale: MOLECULAR
  description: >
    Transmitochondrial cybrid experiments — in which patient
    Epstein-Barr-virus-transformed lymphoblasts were enucleated and fused to
    a mtDNA-deficient recipient cell line — assign a partial complex I
    biochemical defect directly to the ND6 m.14459G>A mutation, separating
    the mtDNA effect from nuclear genetic background. Submitochondrial
    particles from patient cell lines showed a 60% reduction in complex
    I-specific activity relative to controls, with normal activity for
    complexes II+III, III, and IV; cybrid lines carrying the mutation showed
    a smaller but still significant 39% reduction. Kinetic analysis found a
    reduced Vmax with unchanged Km, and specific activity was inhibited by
    increasing concentrations of a reduced coenzyme Q analog (decylubiquinol),
    suggesting the mutation alters the coenzyme Q-binding site of the enzyme
    rather than abolishing catalysis outright.
  molecular_functions:
  - preferred_term: NADH dehydrogenase (ubiquinone) activity
    term:
      id: GO:0008137
      label: NADH dehydrogenase (ubiquinone) activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  evidence:
  - reference: PMID:8622678
    reference_title: "Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Enzymologic analysis of mitochondrial NADH dehydrogenase (complex I) with submitochondrial particles isolated from Epstein-Barr virus-transformed lymphoblasts revealed a 60% reduction (P < 0.005) of complex I-specific activity in patient cell lines compared with controls, with no differences in enzymatic activity for complexes II plus III, III and IV."
    explanation: Directly measures the complex I-specific biochemical defect in patient-derived cell lines.
  - reference: PMID:8622678
    reference_title: "Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Cybrids harboring the np 14459 mutation exhibited a 39% reduction (p < 0.02) in complex I-specific activity relative to wild-type cybrid lines but normal activity for the other complexes."
    explanation: Assigns the complex I defect directly to the mtDNA mutation using cybrids, isolating it from nuclear background effects.
  - reference: PMID:8622678
    reference_title: "Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "specific activity was inhibited by increasing concentrations of the reduced coenzyme Q analog decylubiquinol. These observations suggest that the np 14459 mutation may alter the coenzyme Q-binding site of complex I."
    explanation: Provides the specific biochemical hypothesis for how the mutation impairs complex I function.
  downstream:
  - target: Oxidative Phosphorylation Deficiency and Redox Imbalance
    description: >
      Reduced NADH dehydrogenase activity impairs electron transfer from
      NADH to ubiquinone, lowering the coupled ATP-generating capacity of
      oxidative phosphorylation and predisposing to redox imbalance.
    evidence:
    - reference: PMID:14735585
      reference_title: "Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "MRI of the brain demonstrated bilateral, symmetric basal ganglia lucencies associated with cerebral and systemic lactic acidosis."
      explanation: Clinical lactic acidosis is the systemic biochemical signature of the underlying oxidative phosphorylation deficit.

- name: Oxidative Phosphorylation Deficiency and Redox Imbalance
  biological_scale: CELLULAR
  description: >
    The combination of reduced electron flux through complex I and altered
    coenzyme Q utilization lowers ATP output and predisposes to a chronic
    bioenergetic deficit. Cerebral and systemic lactic acidosis, documented
    on brain MR spectroscopy and blood/CSF chemistry in affected pedigrees,
    is the clinical correlate of this impaired oxidative metabolism.
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: mitochondrial electron transport, NADH to ubiquinone
    term:
      id: GO:0006120
      label: mitochondrial electron transport, NADH to ubiquinone
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  evidence:
  - reference: PMID:14735585
    reference_title: "Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI of the brain demonstrated bilateral, symmetric basal ganglia lucencies associated with cerebral and systemic lactic acidosis."
    explanation: Documents the clinical redox/metabolic correlate (lactic acidosis) accompanying the basal ganglia lesions.
  downstream:
  - target: Tissue-Selective Neuronal Bioenergetic Vulnerability
    description: >
      A generalized, systemic bioenergetic deficit is converted into a
      tissue-restricted disease by the disproportionate vulnerability of
      specific long-axon, high-energy-demand neuronal populations.
    evidence:
    - reference: PMID:19001017
      reference_title: "Inherited mitochondrial optic neuropathies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The selective vulnerability of retinal ganglion cells (RGCs)"
      explanation: Establishes the general principle of selective neuronal vulnerability underlying mitochondrial optic neuropathies, which LDYT extends to a second, striatal cell population.

- name: Tissue-Selective Neuronal Bioenergetic Vulnerability
  biological_scale: CELLULAR
  description: >
    Two neuronal populations with disproportionately high, spatially
    distributed ATP demand are selectively vulnerable to the complex I
    defect: retinal ganglion cells, whose long, partly unmyelinated
    intraretinal axons (as in classical LHON) impose an especially high
    energy burden, and striatal projection neurons of the basal ganglia.
    Why these two populations specifically decompensate, while most other
    tissues remain clinically unaffected, is not fully resolved, but tissue-
    and cell-type-specific mutant load (heteroplasmy) is the best-supported
    explanation: a Japanese series found homoplasmic mutant load producing
    infantile dystonia while a heteroplasmic variant of the same mutation
    produced later-onset truncal ataxia and parkinsonism, and involvement of
    the visual pathway is generally a later event than dystonia in patients
    who develop both.
  cell_types:
  - preferred_term: Retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  - preferred_term: Medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:40190371
    reference_title: "Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This was seen in a Japanese series with homoplasmic mutations resulting in infantile dystonia and heteroplasmic variant showing a later juvenile onset truncal ataxia and parkinsonism."
    explanation: Supports tissue- and load-dependent selective vulnerability as the basis for divergent phenotypes from the same mtDNA variant.
  - reference: PMID:40190371
    reference_title: "Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The involvement of visual pathways in 14459G>A-mutated patients is generally a later event in contrast to dystonia that develops in the early childhood."
    explanation: Documents the differential temporal vulnerability of the two affected neuronal populations.
  downstream:
  - target: Retinal Ganglion Cell Degeneration and Optic Atrophy
    description: >
      In individuals whose bioenergetic threshold is crossed in the visual
      pathway, retinal ganglion cells degenerate, producing optic atrophy
      and central vision loss.
    evidence:
    - reference: PMID:32045392
      reference_title: "Clinical Features of Chinese Sporadic Leber Hereditary Optic Neuropathy Caused by Rare Primary mtDNA Mutations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The patient with LHON plus dystonia demonstrated optic atrophy and increased T2 signal in basal ganglia."
      explanation: Documents optic atrophy occurring alongside basal ganglia disease in the single m.14459G>A LHON-plus-dystonia patient of this cohort.
  - target: Striatal Neurodegeneration and Bilateral Basal Ganglia Necrosis
    description: >
      In individuals whose bioenergetic threshold is crossed in the
      striatum, medium spiny projection neurons of the caudate and putamen
      degenerate, producing bilateral basal ganglia lesions ranging from
      MRI/CT lucencies to frank necrosis.
    evidence:
    - reference: PMID:20052369
      reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Brain MRI showed the presence of bilateral symmetric tissue losses in both the putamen and caudate nucleus"
      explanation: Documents the specific striatal structures (putamen and caudate nucleus) affected by bilateral necrosis.

- name: Retinal Ganglion Cell Degeneration and Optic Atrophy
  biological_scale: TISSUE
  description: >
    As in classical LHON, retinal ganglion cell loss produces progressive
    optic nerve atrophy and permanent central visual impairment. Optic
    atrophy and increased T2 signal on optic-nerve/orbital MRI are the
    imaging correlates, and central scotoma with dyschromatopsia are the
    characteristic visual-field and color-vision consequences when this
    branch of the disease is expressed.
  cell_types:
  - preferred_term: Retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  - preferred_term: optic nerve
    term:
      id: UBERON:0000941
      label: cranial nerve II
  evidence:
  - reference: PMID:32045392
    reference_title: "Clinical Features of Chinese Sporadic Leber Hereditary Optic Neuropathy Caused by Rare Primary mtDNA Mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain MRI T2 short tau inversion recovery sequences demonstrated optic atrophy in 62.5% (10/16); increased T2 signal in the optic nerve was found in 38% (6/16) of patients."
    explanation: Quantifies optic atrophy and optic-nerve T2 signal change in a rare-primary-mutation LHON cohort that includes the m.14459G>A LHON-plus-dystonia patient.
  downstream:
  - target: Optic Atrophy
    description: >
      Retinal ganglion cell and axonal loss culminates in the clinical
      endpoint of bilateral optic atrophy and permanent central visual
      impairment, on the same visual pathway affected in classical LHON.
    evidence:
    - reference: PMID:36317462
      reference_title: "The top 10 most frequently involved genes in hereditary optic neuropathies in 2186 probands."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The positive diagnosis rate in individuals referred for Leber hereditary optic neuropathy testing was 18% (199/1126 index cases), with 92% (184/199) carrying one of the three main pathogenic variants of mitochondrial DNA (m.11778G>A, 66.5%; m.3460G>A, 15% and m.14484T>C, 11%)."
      explanation: Establishes that m.14459G>A LDYT-type optic neuropathy is a rare residual fraction of diagnosed LHON, distinguishing it as a mechanistically related but numerically minor variant class within the same clinical endpoint.

- name: Striatal Neurodegeneration and Bilateral Basal Ganglia Necrosis
  biological_scale: TISSUE
  description: >
    Bilateral, usually symmetric degeneration of the caudate nucleus and
    putamen produces the neuroimaging hallmark of LDYT: bilateral basal
    ganglia lucencies on CT or MRI, which can progress to frank necrosis.
    This lesion is the anatomical substrate for the disease's dystonic and
    associated pyramidal/bulbar features.
  cell_types:
  - preferred_term: Medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  locations:
  - preferred_term: putamen
    term:
      id: UBERON:0001874
      label: putamen
  - preferred_term: caudate nucleus
    term:
      id: UBERON:0001873
      label: caudate nucleus
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  evidence:
  - reference: PMID:20052369
    reference_title: "Pediatric-onset dystonia associated with bilateral striatal necrosis and G14459A mutation in a Korean family: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we describe a Korean family presenting with pediatric-onset, progressive, generalized dystonia with bilateral striatal necrosis and the homoplasmic G14459A mutation in the mitochondrial ND6 gene"
    explanation: Documents bilateral striatal necrosis as the neuroimaging correlate of the disease in a homoplasmic m.14459G>A family.
  - reference: PMID:28503604
    reference_title: "A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showing bilateral magnetic resonance imaging lesions in nucleus pallidus and putamen"
    explanation: Documents the specific basal ganglia nuclei (globus pallidus and putamen) affected in two further m.14459G>A cases.
  downstream:
  - target: Generalized Dystonia
    description: >
      Striatal projection neuron loss disrupts basal ganglia-thalamocortical
      motor circuits, producing progressive generalized dystonia, often
      accompanied by spasticity, dysarthria, and gait impairment.
    evidence:
    - reference: PMID:7654063
      reference_title: "Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "As the first genetic abnormality that has been identified to cause generalized dystonia, this mutation suggests that nuclear DNA or mitochondrial DNA mutations in oxidative phosphorylation genes are important considerations in the pathogenesis of dystonia."
      explanation: States the direct causal link between this mtDNA-encoded complex I lesion and clinical generalized dystonia.

biochemical:
- name: Lactate
  presence: INCREASED
  context: >-
    Cerebral and/or systemic lactic acidosis has been documented alongside
    the bilateral basal ganglia lesions in some LDYT pedigrees, consistent
    with the underlying complex I oxidative phosphorylation deficiency, but
    is not universally present or required for diagnosis.
  readouts:
  - target: Oxidative Phosphorylation Deficiency and Redox Imbalance
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated lactate/pyruvate is the clinical biochemical correlate of the underlying complex I-driven oxidative phosphorylation deficit.
    evidence:
    - reference: PMID:31776719
      reference_title: "Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Venous lactate and pyruvate were elevated (4mM, with normal values 0.5\u20132.2 mM, and 0.23 mM, with normal values 0.03\u20130.15 mM, respectively)."
      explanation: Quantifies elevated venous lactate and pyruvate in a genetically confirmed complex I mtDNA LHON-plus-dystonia patient.
  evidence:
  - reference: PMID:14735585
    reference_title: "Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI of the brain demonstrated bilateral, symmetric basal ganglia lucencies associated with cerebral and systemic lactic acidosis."
    explanation: Documents cerebral and systemic lactic acidosis co-occurring with the basal ganglia lesions in an m.14459G>A pedigree.

classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  mechanistic_category:
  - classification_value: mitochondrial disease

genetic:
- name: MT-ND6
  gene_term:
    preferred_term: MT-ND6
    term:
      id: hgnc:7462
      label: MT-ND6
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: MT-ND6 m.14459G>A
  association: >
    The homoplasmic or heteroplasmic m.14459G>A variant (p.Ala72Val) is the
    predominant molecular cause of LDYT, identified in maternal pedigrees of
    diverse ancestry and, in a minority of cases, as a de novo heteroplasmic
    occurrence.
  evidence:
  - reference: PMID:8016139
    reference_title: "A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the np 14459 G-to-A missense mutation is specific to this family, alters a moderately conserved amino acid in a complex I gene, is a unique mtDNA variant in Native American haplogroup D, and is heteroplasmic, suggesting that it is the disease-causing mutation"
    explanation: Original genetic evidence identifying the m.14459G>A MT-ND6 variant as the disease-causing mutation.

environmental:
- name: Tobacco Smoking
  exposure_term:
    preferred_term: exposure to tobacco smoking
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
  influences_mechanisms:
  - target: Tissue-Selective Neuronal Bioenergetic Vulnerability
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Mitochondrial-toxic exposures are thought to further load a
      bioenergetic system already compromised by the primary complex I
      lesion, pushing vulnerable retinal ganglion cells and striatal neurons
      past a functional threshold. This is the same penetrance-gating logic
      established for classical LHON; the quantitative smoking-penetrance
      study underlying it (93% clinical penetrance in male smokers) was
      conducted in classical LHON pedigrees, not specifically in m.14459G>A
      LDYT families, so the link is extrapolated rather than independently
      demonstrated for this entity.
    evidence:
    - reference: PMID:20301353
      reference_title: "Leber Hereditary Optic Neuropathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals in whom a LHON-causing mtDNA variant has been identified should be strongly advised not to smoke and to moderate alcohol intake, avoiding binge-drinking episodes."
      explanation: GeneReviews advises carriers of any LHON-causing mtDNA variant, the class that includes MT-ND6 m.14459G>A, to avoid smoking; recorded PARTIAL because the underlying penetrance evidence was generated in classical LHON cohorts rather than in LDYT pedigrees specifically.
  description: >
    General LHON avoidance counselling (no smoking) is extrapolated to LDYT
    carriers because the underlying complex I lesion and bioenergetic
    threshold logic are shared with classical LHON, even though
    smoking-penetrance data have not been separately generated for
    m.14459G>A pedigrees.
  effect: Extrapolated risk modifier for symptomatic conversion; not independently established for LDYT
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "strongly advised not to smoke and to moderate alcohol intake, avoiding binge-drinking episodes"
    explanation: GeneReviews' avoidance recommendation for carriers of any LHON-causing mtDNA variant; extrapolated to LDYT rather than separately demonstrated.
- name: Heavy Alcohol Intake
  exposure_term:
    preferred_term: exposure to alcohol consumption
    term:
      id: ECTO:0001082
      label: exposure to alcohol consumption
  influences_mechanisms:
  - target: Tissue-Selective Neuronal Bioenergetic Vulnerability
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Alcohol is grouped with the same bioenergetic-threshold logic as
      smoking. As with smoking, the recommendation to moderate intake is
      GeneReviews' general LHON guidance applied here; no LDYT-specific
      alcohol-penetrance study was identified.
    evidence:
    - reference: PMID:20301353
      reference_title: "Leber Hereditary Optic Neuropathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "to moderate alcohol intake, avoiding binge-drinking episodes"
      explanation: GeneReviews advises moderating alcohol intake for carriers of any LHON-causing mtDNA variant; extrapolated to LDYT rather than separately demonstrated.
  description: >
    Moderation of alcohol intake and avoidance of binge drinking is
    extrapolated general LHON counselling; no LDYT-specific quantitative
    alcohol-penetrance data were identified.
  effect: Extrapolated, weakly supported risk modifier; not independently established for LDYT
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to moderate alcohol intake, avoiding binge-drinking episodes"
    explanation: GeneReviews' avoidance recommendation for carriers of any LHON-causing mtDNA variant; extrapolated to LDYT rather than separately demonstrated.
- name: Mitochondrial-Toxic Drug Exposure
  exposure_term:
    preferred_term: exposure to mitochondrial NADH:ubiquinone reductase inhibitor
    term:
      id: ECTO:9001785
      label: exposure to mitochondrial NADH:ubiquinone reductase inhibitor
  influences_mechanisms:
  - target: Tissue-Selective Neuronal Bioenergetic Vulnerability
    environmental_effect: EXACERBATES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      A drug that itself inhibits complex I NADH:ubiquinone oxidoreductase
      activity would add to, rather than merely coexist with, the primary
      m.14459G>A lesion's own effect on the same enzyme, plausibly
      accelerating the same bioenergetic-threshold logic as smoking and
      alcohol. This is a mechanistic extrapolation from GeneReviews' general
      avoidance advice rather than an LDYT-specific dosing or exposure study.
    evidence:
    - reference: PMID:20301353
      reference_title: "Leber Hereditary Optic Neuropathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "drugs with mitochondrial toxic effects"
      explanation: GeneReviews recommends avoiding drugs with mitochondrial toxic effects for carriers of any LHON-causing mtDNA variant; extrapolated to LDYT and to the complex I-specific ECTO term rather than separately demonstrated.
  description: >
    GeneReviews recommends carriers of any LHON-causing mtDNA variant avoid
    head trauma, industrial toxins, and drugs with mitochondrial toxic
    effects generally; the complex I-specific ECTO term used here is a
    reasonable mechanistic fit for a disease already defined by a complex I
    lesion, but no LDYT- or m.14459G>A-specific study of this exposure class
    was identified.
  effect: Extrapolated risk modifier; not independently established for LDYT
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It would be reasonable to avoid exposure to other putative environmental triggers for visual loss, such as head trauma, industrial toxins, and drugs with mitochondrial toxic effects."
    explanation: GeneReviews' general recommendation to avoid mitochondrial-toxic drugs and other environmental triggers for carriers of any LHON-causing mtDNA variant.

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: RARE
  notes: >-
    No population-based prevalence or incidence estimate has been published
    for LDYT specifically; it is known only from isolated case reports and
    small maternal pedigrees (fewer than a dozen published families/case
    series across Hispanic/Native American, Korean, Japanese, Chinese, and
    other ancestries), distinct from the population-based prevalence figures
    available for classical LHON (see the sibling Leber_Hereditary_Optic_
    Neuropathy.yaml entry).
  evidence:
  - reference: PMID:31776719
    reference_title: "Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The association of LHON with spastic dystonia (LDYT) is also rare (OMIM#500001)"
    explanation: States directly that LDYT is a rare presentation, distinct from classical LHON.

diagnosis:
- name: Targeted then Complete mtDNA Sequencing with Heteroplasmy Quantification
  description: >
    Diagnosis rests on identifying a complex I mtDNA variant, most often
    m.14459G>A in MT-ND6, in a proband with optic neuropathy and/or dystonia
    plus bilateral basal ganglia lesions. Because mutant load can differ
    substantially between tissues, testing more than one accessible tissue
    (blood, urine sediment, buccal mucosa, or skin fibroblasts) is important
    when a low-level or discordant heteroplasmy result is suspected, rather
    than relying on blood alone.
  evidence:
  - reference: PMID:28503604
    reference_title: "A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The heteroplasmy level in the urinary sediment was 91% and in buccal mucosa 89% in patient 1, but in patient 2 the heteroplasmy level was 59% in fibroblasts."
    explanation: Documents markedly tissue-dependent heteroplasmy levels for the m.14459G>A variant across urine sediment, buccal mucosa, and fibroblasts, supporting multi-tissue testing.
  - reference: PMID:28503604
    reference_title: "A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Total DNA was extracted from skeletal muscle, skin fibroblasts, blood, urinary sediment, and buccal smears"
    explanation: Documents the panel of accessible tissues sampled for mtDNA heteroplasmy testing in genetically confirmed cases.
- name: Targeted mtDNA Testing for the Three Common LHON Variants First
  description: >
    Because the three common LHON mtDNA variants account for the great
    majority of molecularly diagnosed LHON, targeted testing for these
    should be performed first even when dystonia or basal ganglia disease
    accompanies the optic neuropathy; only when this is negative does
    testing proceed to complete mtDNA sequencing that can detect m.14459G>A
    and other rare complex I loci.
  evidence:
  - reference: PMID:36317462
    reference_title: "The top 10 most frequently involved genes in hereditary optic neuropathies in 2186 probands."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "92% (184/199) carrying one of the three main pathogenic variants of mitochondrial DNA (m.11778G>A, 66.5%; m.3460G>A, 15% and m.14484T>C, 11%)"
    explanation: Quantifies that the three common LHON variants explain the great majority of molecularly diagnosed LHON, supporting them as the appropriate first-line targeted test before broader mtDNA sequencing that would detect rarer LDYT-associated loci.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of LHON is established in a proband with a consistent clinical history and/or one of three common mitochondrial DNA (mtDNA) pathogenic variants identified on molecular genetic testing."
    explanation: GeneReviews defines the general LHON diagnostic basis around the three common variants; recorded PARTIAL because LDYT commonly requires testing beyond those three, which is exactly the nuance captured by this entry's first diagnosis entry.

treatments:
- name: Idebenone
  description: >
    A short-chain quinone that can bypass a defective complex I by
    accepting electrons via NQO1 and delivering them downstream to complex
    III. It is authorised for LHON generally (EMA, exceptional
    circumstances) but its benefit has not been separately established for
    the LDYT/dystonia phenotype specifically.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: idebenone
      term:
        id: CHEBI:31687
        label: idebenone
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Idebenone (Raxone\u00ae) has been approved for the treatment of LHON by the European Medicines Agency under exceptional circumstances."
    explanation: GeneReviews documents EMA approval and some visual benefit for idebenone in LHON generally; recorded as PARTIAL because the benefit is established for LHON broadly, not specifically for the LDYT/dystonia phenotype modeled in this entry.
- name: Oral Dystonia Pharmacotherapy Trial
  description: >
    Empiric oral dystonia agents (levodopa, baclofen, tizanidine) have been
    trialed in LDYT; non-response has been documented in at least one
    genetically confirmed case, consistent with LDYT being a
    non-dopa-responsive dystonia. This contrasts with the symptomatic relief
    obtained from botulinum toxin and deep brain stimulation in other
    reported cases.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:40190371
    reference_title: "Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her generalized dystonia was non-responsive to L-dopa, baclofen, and tizanidine treatment trials."
    explanation: Documents non-response to standard oral dystonia agents in a genetically confirmed m.14459G>A LDYT patient, the negative but clinically informative finding behind the description's non-dopa-responsive characterization.
- name: Visual Aids and Occupational Rehabilitation
  description: >
    General LHON supportive care (visual aids, occupational rehabilitation,
    and registration with relevant social services) is the standard
    management for the optic-neuropathy branch of LDYT, extrapolated from
    LHON overall since no LDYT-specific supportive-care study exists.
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management of affected individuals remains mostly supportive, and includes provision of visual aids, occupational rehabilitation, and registration with the relevant social services."
    explanation: GeneReviews' general LHON supportive-care recommendation; recorded PARTIAL because it is written for LHON overall rather than demonstrated specifically in LDYT.
- name: Multidisciplinary Management of Extraocular Neurologic Features
  description: >
    A multidisciplinary approach (neurology, physical/occupational therapy,
    and cardiology) is recommended for the extraocular neurologic features
    of LHON-plus disease, which is directly on point for LDYT since its
    defining feature is extraocular (dystonia, ataxia, peripheral
    neuropathy). Cardiology referral is additionally recommended for any
    LHON-causing mtDNA variant carrier found to have pre-excitation on EKG.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A multidisciplinary approach for those affected individuals with extraocular neurologic features (ataxia, peripheral neuropathy, nonspecific myopathy, and movement disorders) should be considered to minimize the functional consequences of these complications."
    explanation: GeneReviews recommends multidisciplinary management specifically for the extraocular neurologic features that define LHON-plus disease, directly applicable to LDYT's dystonia/ataxia presentation.
  - reference: PMID:20301353
    reference_title: "Leber Hereditary Optic Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Referral to a cardiologist for individuals with pre-excitation syndrome on EKG is recommended; treatment for symptomatic individuals is per standard practice."
    explanation: GeneReviews' general LHON recommendation for cardiology referral on EKG pre-excitation; recorded PARTIAL because it is written for LHON overall rather than demonstrated specifically in LDYT pedigrees.
- name: Botulinum Toxin Injection
  description: >
    Used for symptomatic relief of focal or segmental dystonic posturing,
    for example of the arm, in LDYT patients with generalized dystonia.
  treatment_term:
    preferred_term: botulinum toxin therapy
    term:
      id: NCIT:C157775
      label: Botulinum Toxin Therapy
  evidence:
  - reference: PMID:28503604
    reference_title: "A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he has received significant symptomatic relief with Botox injections"
    explanation: Documents symptomatic benefit from botulinum toxin injection for dystonic limb posturing in a genetically confirmed m.14459G>A case.
- name: Globus Pallidus Internus Deep Brain Stimulation
  description: >
    Considered for medically refractory generalized dystonia in LDYT,
    extrapolated from its established use in other genetic and idiopathic
    dystonias; no LDYT-specific response rate has been established.
  treatment_term:
    preferred_term: deep brain stimulation
    term:
      id: NCIT:C21024
      label: Deep Brain Stimulation
  evidence:
  - reference: PMID:40190371
    reference_title: "Adult-Onset Bilateral Optic Neuropathy in a Patient with Non-Familial Childhood-Onset Generalized Dystonia Associated with Mitochondrial DNA 14459G>A Mutation: A Case Report and Review of Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "she was implanted with a Bilateral Globus Pallidus Internal Deep Brain Stimulator (DBS) at age 15 years"
    explanation: Documents bilateral globus pallidus internus DBS used to manage refractory generalized dystonia in a genetically confirmed m.14459G>A LDYT patient.

datasets: []
📚

References & Deep Research

References

1
PMID:20301353
Leber Hereditary Optic Neuropathy.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 11 citations 2026-08-17T21:11:16.524788

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Leber Optic Atrophy and Dystonia
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Leber Optic Atrophy and Dystonia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Leber hereditary optic neuropathy with dystonia: disease-characteristics report

Executive summary and entity clarification

Leber optic atrophy and dystonia is best interpreted as Leber hereditary optic neuropathy with dystonia (LHON-dystonia; LHOND), a very rare mitochondrial disorder classically associated with the MT-ND6 m.14459G>A mitochondrial-DNA variant. It combines an LHON-like optic neuropathy with dystonia and basal-ganglia disease. It is not Mohr–Tranebjærg/deafness-dystonia-optic-neuronopathy syndrome, which is an X-linked nuclear disorder caused by TIMM8A variants. Open Targets likewise places MT-ND genes centrally in LHON and associates TIMM8A only with the broader hereditary-optic-neuropathy category. (OpenTargets Search: Leber optic atrophy and dystonia, yuwaiman2009inheritedmitochondrialoptic pages 10-10)

The subtype is so rare that most evidence consists of pedigrees, case reports, small cohorts, and transmitochondrial cybrid experiments. Consequently, prevalence, penetrance, phenotype frequencies, validated prognostic biomarkers, and treatment-response rates specific to LHOND remain unknown.

domain established finding evidence type key quantitative detail source/year/DOI or PMID if present confidence/limitations
Entity resolution The requested disease is best resolved as mitochondrial Leber hereditary optic neuropathy with dystonia (LHON-dystonia/LHOND), not TIMM8A-related Mohr-Tranebjaerg syndrome. TIMM8A disease is an X-linked nuclear mitochondrial import disorder with hearing-loss–predominant phenotype, whereas LHON-dystonia is a maternal mtDNA disorder centered on optic neuropathy plus movement disorder. (OpenTargets Search: Leber optic atrophy and dystonia, yuwaiman2009inheritedmitochondrialoptic pages 10-10) Review/database-supported disease distinction Open Targets links TIMM8A to hereditary optic neuropathy only weakly, while classic LHON disease associations center on mtDNA complex I genes; TIMM8A review states pathogenic variants cause Mohr-Tranebjaerg syndrome. Heinemeyer et al., 2019, DOI: 10.1089/dna.2018.4292; Open Targets context (OpenTargets Search: Leber optic atrophy and dystonia) Moderate confidence for distinction; exact MONDO/OMIM mapping for the rare LHON-dystonia label not directly retrieved here.
Primary causal variant The canonical variant for LHON-dystonia is MT-ND6 m.14459G>A. It has long been reported in maternally inherited families with optic neuropathy and dystonia and remains the main genotype linked to this entity. (yuwaiman2009inheritedmitochondrialoptic pages 10-10, cui2020clinicalfeaturesof pages 6-6) Primary literature summarized in review; clinical cohort context In a 2020 Chinese rare-mutation LHON series, 4/16 patients carried m.14459G>A; 1 had LHON plus dystonia. Cui et al., 2020, J Neuro-Ophthalmol, DOI: 10.1097/WNO.0000000000000799 High confidence that m.14459G>A is disease-defining; low sample size for phenotype frequencies.
Additional genetic heterogeneity LHON-plus phenotypes with dystonia can also occur with other mtDNA complex I variants or double mutations, but these are not the classic LHON-dystonia entity. (berardo2020leberhereditaryoptic pages 1-3, yuwaiman2009inheritedmitochondrialoptic pages 10-10) Case report + review A 2020 case had double MT-ND4/MT-ND6 mutations with optic neuropathy, dystonia, and transverse myelitis; not a pure m.14459G>A-only presentation. Berardo et al., 2020, DOI: 10.1007/s00415-019-09619-z Moderate confidence; demonstrates phenotypic overlap, not primary disease definition.
Inheritance LHON-dystonia follows maternal (mitochondrial) inheritance because the causal variants are in mtDNA. (berardo2020leberhereditaryoptic pages 1-3, yuwaiman2009inheritedmitochondrialoptic pages 10-10) Review + case report General LHON shows maternal transmission and incomplete penetrance; most primary LHON mutations are often homoplasmic. Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270; Berardo et al., 2020, DOI: 10.1007/s00415-019-09619-z High confidence for inheritance; penetrance estimates specific to m.14459G>A were not retrieved.
Heteroplasmy/homoplasmy Published LHON literature indicates many primary LHON mutations are homoplasmic, and review evidence specifically notes homoplasmic inheritance has been described with m.14459G>A despite variable clinical expression. (berardo2020leberhereditaryoptic pages 1-3, yuwaiman2009inheritedmitochondrialoptic pages 10-10) Review/case-based synthesis No robust disease-specific heteroplasmy percentage retrieved for LHON-dystonia. Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270 Moderate confidence; variant-level quantitative heteroplasmy data are sparse in the retrieved evidence.
Mechanism: biochemical lesion MT-ND6 m.14459G>A causes a respiratory chain complex I defect. Cybrid experiments were used to assign the defect directly to the mtDNA variant. (yuwaiman2009inheritedmitochondrialoptic pages 10-10) Functional primary study summarized in review The key mechanistic assignment was made in transmitochondrial cybrids. Jun et al., 1996, Mol Cell Biol, DOI: 10.1128/MCB.16.3.771 High confidence for mechanism; original article text was not directly extracted here, but the review cites it specifically.
Mechanism: cell injury cascade General LHON pathophysiology supports that complex I dysfunction drives reduced oxidative phosphorylation, oxidative stress, impaired glutamate handling, and increased apoptotic susceptibility in retinal ganglion cells; these mechanisms are used to explain LHON-dystonia as a complex I neurodegenerative phenotype. (yuwaiman2009inheritedmitochondrialoptic pages 10-10) Review of cellular/model studies No LHON-dystonia-specific omics dataset retrieved; mechanism largely extrapolated from LHON/cybrid work. Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270 Moderate confidence; strong biological plausibility but limited subtype-specific mechanistic profiling.
Core phenotype The syndrome combines Leber hereditary optic neuropathy with dystonia; dystonia may precede ocular manifestations by years in mtDNA movement-disorder literature summarized by reviews. (yuwaiman2009inheritedmitochondrialoptic pages 10-10) Review of case reports/families No pooled frequency estimate for dystonia among m.14459G>A carriers retrieved. Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270 Moderate confidence; based mainly on rare families/case reports.
MRI / neuroimaging In rare-mutation LHON, MRI can show optic atrophy and optic pathway signal changes; in the patient with m.14459G>A plus dystonia, MRI also showed basal ganglia T2 signal abnormalities. (cui2020clinicalfeaturesof pages 6-6) Clinical cohort In the 16-patient series: optic atrophy in 62.5% (10/16); increased optic-nerve T2 signal in 38% (6/16); the single LHON+dystonia patient had basal-ganglia signal change. Cui et al., 2020, DOI: 10.1097/WNO.0000000000000799 Moderate confidence; useful radiologic clue, but data come from a small rare-mutation cohort.
Visual severity / course Rare-mutation LHON generally causes substantial visual disability; in the same cohort most eyes were severely impaired. (cui2020clinicalfeaturesof pages 6-6) Clinical cohort 75% (24/32 eyes) had worst Snellen BCVA ≤0.1; mean onset age in the cohort was 15 ± 6 years; male:female 15:1. Cui et al., 2020, DOI: 10.1097/WNO.0000000000000799 Moderate confidence for rare-mutation LHON context; not specific to all LHON-dystonia cases.
Environmental / modifier factors General LHON penetrance is modified by sex, mtDNA background/haplogroup, and reported environmental triggers such as tobacco and alcohol; estrogen has been discussed as potentially protective. (berardo2020leberhereditaryoptic pages 1-3) Review/case-report background No LHON-dystonia-specific exposure study retrieved. Berardo et al., 2020, DOI: 10.1007/s00415-019-09619-z Moderate confidence for LHON overall; low confidence for direct subtype-specific effect sizes.
2023 diagnostic cohort context A large 2023 hereditary optic neuropathy diagnostic series provides context for how unusual LHON-dystonia is relative to standard LHON. Among index cases diagnosed with LHON, the vast majority carried the 3 common LHON variants rather than rare variants like m.14459G>A. Large retrospective diagnostic cohort Positive LHON diagnosis in 199/1,126 (18%) index cases; among these, 92% (184/199) had one of 3 major mtDNA variants: m.11778G>A 66.5%, m.3460G>A 15%, m.14484T>C 11%. Rocatcher et al., 2023, Brain, DOI: 10.1093/brain/awac395 High confidence for diagnostic context; does not specifically enumerate LHON-dystonia.
Diagnostic approach Diagnosis should integrate neuro-ophthalmic phenotype with mtDNA testing, especially for primary LHON variants and rarer complex I variants in atypical/LHON-plus cases; MRI abnormalities do not exclude LHON. (cui2020clinicalfeaturesof pages 6-6) Clinical cohort + general disease context MRI optic pathway signal abnormality occurred in 38% of the rare-mutation cohort, underscoring that inflammatory-appearing imaging can still occur in LHON. Cui et al., 2020, DOI: 10.1097/WNO.0000000000000799 Moderate confidence; no formal subtype-specific guideline retrieved.
Current management There is no established disease-specific therapy for LHON-dystonia. Management is extrapolated from LHON and movement-disorder care: visual rehabilitation, mitochondrial counseling, and symptomatic dystonia treatment. (berardo2020leberhereditaryoptic pages 1-3, yuwaiman2009inheritedmitochondrialoptic pages 10-10) Review/case-based practice inference No controlled trial specific to m.14459G>A LHON-dystonia retrieved. Berardo et al., 2020, DOI: 10.1007/s00415-019-09619-z; Yu-Wai-Man et al., 2009, DOI: 10.1136/jmg.2007.054270 Moderate confidence; evidence gap for subtype-directed treatment.
Trials / real-world implementation Recent interventional development is concentrated in general LHON, especially ND4 gene therapy rather than m.14459G>A LHON-dystonia. Active/completed trials include NCT07406854, NCT05293626, NCT03406104, NCT03293524, NCT03153293, NCT02064569, NCT01267422, and nicotinamide/metabolomics studies. (OpenTargets Search: Leber optic atrophy and dystonia) Clinical trial registry Example enrollments: 95 (NCT07406854), 98 (NCT03293524), 159 (NCT03153293), 19 (NCT02064569). ClinicalTrials.gov records via tool context (OpenTargets Search: Leber optic atrophy and dystonia) High confidence that therapeutic development is active in LHON broadly; none retrieved were specific to MT-ND6 m.14459G>A dystonia.
Evidence gaps Major gaps remain in epidemiology, penetrance, natural history, modifier genes, formal diagnostic criteria, biomarkers, prognosis, and animal/subtype-specific models for LHON-dystonia. Most evidence derives from isolated families, case reports, or broader LHON reviews. (berardo2020leberhereditaryoptic pages 1-3, yuwaiman2009inheritedmitochondrialoptic pages 10-10, cui2020clinicalfeaturesof pages 6-6) Evidence synthesis No robust prevalence/incidence estimate or prospective natural-history cohort specific to LHON-dystonia was retrieved. Based on retrieved literature set (berardo2020leberhereditaryoptic pages 1-3, yuwaiman2009inheritedmitochondrialoptic pages 10-10, cui2020clinicalfeaturesof pages 6-6) High confidence that evidence is sparse due to extreme rarity.

Table: This compact table summarizes the strongest retrieved evidence for Leber hereditary optic neuropathy with dystonia, emphasizing its distinction from TIMM8A disease, the central role of MT-ND6 m.14459G>A, and what is known versus still missing from the literature.

1. Disease information

Definition

LHOND is a Mendelian mitochondrial cytopathy in which a pathogenic mtDNA complex-I variant causes variable combinations of subacute or progressive bilateral optic neuropathy and dystonia. Other neurological manifestations can include bilateral striatal degeneration, ataxia, dysarthria, pyramidal signs, encephalopathy, and—occasionally—broader “LHON-plus” features. MT-ND6 m.14459G>A has been specifically linked to maternally inherited LHON-dystonia. (yuwaiman2009inheritedmitochondrialoptic pages 10-10)

Identifiers and names

  • OMIM: 500001, historically “Leber optic atrophy and dystonia.”
  • MONDO: A distinct subtype identifier was not securely recovered. Use MONDO:0010788, Leber hereditary optic neuropathy, with an explicit dystonia/LHON-plus qualifier rather than assigning an unverified subtype ID.
  • Broader MONDO term: MONDO:0020478, Leber plus disease may also be relevant, but is broader than m.14459G>A LHOND. Open Targets links this category principally to MT-ND1, MT-ND3, MT-ND4, and MT-ND6. (OpenTargets Search: Leber optic atrophy and dystonia)
  • Orphanet: No subtype-specific ORPHA identifier was verified from retrieved evidence.
  • ICD-10: No unique LHOND code. Depending on the coding purpose, broader categories include hereditary optic atrophy/optic-nerve disorders and dystonia; local coding guidance is required.
  • ICD-11/MeSH: No verified subtype-specific term was retrieved; use LHON plus dystonia as compositional coding.
  • Synonyms: LHON with dystonia; LHON-dystonia; LHOND; maternally inherited Leber hereditary optic neuropathy and dystonia; Leber optic atrophy and dystonia; m.14459G>A-associated LHON-plus.

This report synthesizes aggregated disease-level resources and published human families/cases, not patient-level EHR data.

2. Etiology, risk, and protective factors

Causal factors

The canonical cause is a germline mitochondrial-DNA variant, MT-ND6 m.14459G>A, affecting NADH dehydrogenase subunit 6 of respiratory-chain complex I. Functional cybrid work assigned a complex-I defect directly to this mtDNA mutation. (yuwaiman2009inheritedmitochondrialoptic pages 10-10)

Additional mtDNA variants can produce clinically overlapping LHON-plus/dystonia phenotypes. A 2020 report described optic neuropathy, dystonia, ataxia, dysarthria, ptosis, and recurrent transverse myelitis with double MT-ND4 m.11778G>A and MT-ND6 m.14484T>C mutations; this illustrates genetic heterogeneity but should not be collapsed into classic m.14459G>A LHOND. (berardo2020leberhereditaryoptic pages 1-3)

Risk and modifier factors

  • Genetic: mutant load/heteroplasmy, mtDNA haplogroup, nuclear genetic background, sex, and tissue-specific mitochondrial thresholds plausibly modify expression. Most conventional LHON mutations are homoplasmic, and homoplasmic m.14459G>A can still show markedly variable expression, demonstrating that genotype alone does not determine phenotype. (berardo2020leberhereditaryoptic pages 1-3, yuwaiman2009inheritedmitochondrialoptic pages 10-10)
  • Sex: LHON overall has strong male predominance. A rare-mutation Chinese cohort had a male:female ratio of 15:1, although this is not a subtype-specific penetrance estimate. (cui2020clinicalfeaturesof pages 6-6)
  • Environment: smoking and heavy alcohol exposure are recognized general-LHON risk modifiers; mitochondrial toxins and medications should be minimized where clinically feasible. Direct m.14459G>A-specific effect sizes are unavailable. (berardo2020leberhereditaryoptic pages 1-3)
  • Potential protection: estrogen-associated mitochondrial effects have been proposed to contribute to lower female penetrance in LHON. This is mechanistic/observational evidence, not an established preventive treatment. (berardo2020leberhereditaryoptic pages 1-3)
  • Family history: maternal relatives may carry the variant even when clinically unaffected because penetrance is incomplete.

No validated protective allele, diet, supplement, or lifestyle intervention has been demonstrated specifically for LHOND. There is no infectious cause.

3. Phenotypes

Phenotype Clinical characterization Suggested HPO term
Optic neuropathy/optic atrophy Central visual loss, dyschromatopsia and central/cecocentral scotoma; typically bilateral and sequential or simultaneous; may progress to severe permanent visual disability Optic atrophy HP:0000648; Visual loss HP:0000572; Central scotoma HP:0000603; Dyschromatopsia HP:0007641
Dystonia Focal, segmental, or generalized sustained/posturing movements; may precede visual disease by years; severity is highly variable Dystonia HP:0001332; Generalized dystonia HP:0007325
Basal-ganglia degeneration T2 signal changes or bilateral striatal lesions; correlates with dystonia and other movement abnormalities Abnormal basal-ganglia MRI HP:0012758
Ataxia/gait impairment Reported in LHON-plus presentations; affects mobility and independence Ataxia HP:0001251; Gait disturbance HP:0001288
Dysarthria May accompany generalized dystonia or cerebellar/basal-ganglia involvement Dysarthria HP:0001260
Pyramidal signs/weakness Variable and uncommon; should prompt assessment for broader mitochondrial disease Hyperreflexia HP:0001347; Muscle weakness HP:0001324
Ptosis Reported in broader LHON-plus phenotypes, not obligatory for classic LHOND Ptosis HP:0000508

In 16 Chinese patients with rare primary LHON mutations, mean onset was 15 ± 6 years, 24/32 eyes (75%) reached best-corrected visual acuity ≤0.1 (≤20/200), optic atrophy was present in 10/16 (62.5%), and optic-nerve T2 hyperintensity in 6/16 (38%). Four patients carried m.14459G>A, but only one had documented LHON plus dystonia; therefore these aggregate visual percentages must not be interpreted as m.14459G>A-dystonia frequencies. (cui2020clinicalfeaturesof pages 6-6)

Quality-of-life studies specific to LHOND were not found. Expected burden is substantial: central blindness impairs reading, driving and face recognition, while dystonia can impair walking, hand use, speech, feeding, comfort, and social participation.

4. Genetic and molecular information

Primary gene and variant

  • Gene: MT-ND6, mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6.
  • Canonical variant: m.14459G>A, a mitochondrial missense variant commonly described as p.Ala72Val under the standard mitochondrial code/reference framework.
  • Origin: constitutional/germline mtDNA; maternal transmission. It is not a somatic cancer variant.
  • Consequence: altered complex-I membrane-arm function, impaired oxidative phosphorylation, and tissue-selective neuronal degeneration.
  • Population frequency: no reliable frequency suitable for this report was retrieved from population databases; the pathogenic genotype is extremely rare.

A contemporary diagnostic context comes from 2,186 probands evaluated for hereditary optic neuropathy: only 199/1,126 (18%) referred for LHON testing received a molecular diagnosis, and 184/199 (92%) diagnosed cases carried one of the three common variants—m.11778G>A (66.5%), m.3460G>A (15%), or m.14484T>C (11%). Thus rare variants such as m.14459G>A form a small residual fraction. Publication: February 2023, DOI: https://doi.org/10.1093/brain/awac395.

Other genetic findings

  • Rare MT-ND1, MT-ND3, MT-ND4, and other MT-ND6 variants can cause LHON-plus or dystonia-overlap phenotypes. Open Targets records associations of MT-ND1, MT-ND3, MT-ND4 and MT-ND6 with Leber-plus disease. (OpenTargets Search: Leber optic atrophy and dystonia)
  • No reproducible nuclear modifier gene specific to m.14459G>A LHOND is established.
  • No disease-specific methylation signature, chromatin abnormality, aneuploidy, translocation, or repeat expansion is established.
  • Large mtDNA deletions and nuclear copy-number variants are not the canonical mechanism.

5. Environmental and lifestyle information

There is no evidence that environmental exposure alone causes LHOND. Rather, environment may alter penetrance in a genetically susceptible carrier. Avoidance of tobacco, excessive alcohol, and unnecessary mitochondrial-toxic exposures is biologically reasonable and standard LHON counseling, but subtype-specific prevention trials are absent. (berardo2020leberhereditaryoptic pages 1-3)

Regular nutrition and exercise within neurological limitations support general health but are not proven to prevent conversion. No pathogen, zoonosis, radiation exposure, occupational agent, or pollution exposure has been causally established.

6. Mechanism and pathophysiology

Causal chain

  1. Upstream genetic lesion: maternal MT-ND6 m.14459G>A.
  2. Primary biochemical defect: altered ND6 impairs mitochondrial respiratory-chain complex I. Transmitochondrial cybrids demonstrated that the variant itself produces the complex-I defect, separating mtDNA causation from nuclear background. (yuwaiman2009inheritedmitochondrialoptic pages 10-10)
  3. Metabolic consequences: impaired electron transport and proton pumping reduce respiratory efficiency/ATP reserve and increase redox imbalance and reactive oxygen species.
  4. Cellular stress: altered mitochondrial membrane potential, calcium handling, glutamate transport, and apoptotic susceptibility promote neuronal injury. General LHON cybrid and retinal models show oxidative injury and enhanced death-signaling susceptibility. (yuwaiman2009inheritedmitochondrialoptic pages 10-10)
  5. Tissue selectivity: small-caliber retinal ganglion cells of the papillomacular bundle and basal-ganglia neurons have high energy demands and long axons, making them vulnerable to limited mitochondrial reserve.
  6. Clinical manifestation: retinal-ganglion-cell and optic-nerve axonal loss produces central blindness; striatal/basal-ganglia injury disrupts motor circuits and produces dystonia.

Suggested ontology annotations

  • GO biological process: mitochondrial electron transport, NADH to ubiquinone (GO:0006120); oxidative phosphorylation (GO:0006119); ATP metabolic process (GO:0046034); response to oxidative stress (GO:0006979); neuron apoptotic process (GO:0051402).
  • GO cellular component: mitochondrion (GO:0005739); mitochondrial inner membrane (GO:0005743); respiratory-chain complex I (GO:0005747).
  • Cell Ontology: retinal ganglion cell (CL:0000740); neuron (CL:0000540); astrocyte (CL:0000127) as a plausible secondary participant.
  • CHEBI: ATP (CHEBI:15422); reactive oxygen species (CHEBI:26523); ubiquinone (CHEBI:16389).

No subtype-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, epigenomic, or multi-omic dataset was identified. Mechanistic inference therefore rests chiefly on biochemical assays, cybrids, general LHON models, imaging, and neuropathology.

7. Anatomical structures affected

  • Primary organ/system: eye and central nervous system.
  • Primary site: retinal ganglion-cell layer, papillomacular bundle, optic nerve, optic chiasm and tracts.
  • Motor site: striatum/basal ganglia, particularly caudate-putamen circuitry; broader brain involvement can occur in LHON-plus disease.
  • Laterality: optic neuropathy is usually bilateral, although onset may be sequential. Basal-ganglia abnormalities are often bilateral.
  • Subcellular site: mitochondrial inner membrane and complex I.

Suggested anatomy terms include retina (UBERON:0000966), optic nerve (UBERON:0000941), optic chiasm (UBERON:0001892), basal ganglion (UBERON:0002420), and mitochondrion (GO:0005739). In the rare-mutation cohort, the m.14459G>A patient with dystonia had optic atrophy and increased basal-ganglia T2 signal. (cui2020clinicalfeaturesof pages 6-6)

8. Temporal development

Onset ranges from childhood through adulthood and varies within maternal pedigrees. Either dystonia or visual loss can occur first; movement disease may precede optic neuropathy by years. Visual loss is usually subacute and subsequently evolves to chronic optic atrophy, whereas dystonia commonly follows a chronic progressive course. (yuwaiman2009inheritedmitochondrialoptic pages 10-10)

A practical—not formally validated—staging framework is:

  1. Carrier/presymptomatic: mtDNA variant present without functional deficits.
  2. Early neurological or ophthalmic disease: dystonia, gait change, dyschromatopsia, central scotoma, or unilateral visual loss.
  3. Established bilateral disease: severe bilateral central visual impairment with persistent or progressive dystonia.
  4. Advanced LHON-plus: generalized dystonia, major mobility/speech impairment, and broader neurological involvement.

Spontaneous visual improvement is possible in LHON generally and varies by genotype, but recovery data specific to m.14459G>A LHOND are insufficient. There is no established remission pattern for the dystonia.

9. Inheritance and population

Inheritance

  • Pattern: mitochondrial/maternal.
  • A carrier mother may transmit the variant to all children; only daughters transmit their mtDNA onward.
  • Penetrance: incomplete, sex- and age-dependent, but no reliable m.14459G>A-specific percentage is available.
  • Expressivity: markedly variable—from asymptomatic carrier, isolated optic neuropathy, or isolated dystonia to combined severe disease.
  • Anticipation: not established.
  • Germline mosaicism: mtDNA heteroplasmy and the mitochondrial bottleneck are more relevant concepts than conventional nuclear germline mosaicism.
  • Consanguinity: not a recognized risk because inheritance is maternal, not autosomal recessive.

Epidemiology

No defensible prevalence, incidence, carrier-frequency, or sex ratio has been established specifically for LHOND. Cases and pedigrees have been reported in multiple ancestries, including Native American, Asian, and European families, arguing against restriction to one population. A founder m.14459G>A variant has been described in some Japanese families, but a global founder effect cannot be assumed.

10. Diagnostics

Clinical evaluation

  1. Neuro-ophthalmology: best-corrected acuity, color vision, pupils, automated perimetry, fundus photography, OCT retinal-nerve-fiber/ganglion-cell analysis, and visual evoked potentials as needed.
  2. Movement-disorder examination: dystonia distribution/severity, gait, ataxia, pyramidal signs, speech and swallowing.
  3. MRI brain and orbits: optic-nerve/chiasmal signal and atrophy; basal-ganglia lesions or striatal atrophy. Optic-pathway T2 hyperintensity does not exclude LHON: it occurred in 38% of the small rare-mutation cohort. (cui2020clinicalfeaturesof pages 6-6)
  4. Laboratory assessment: lactate, pyruvate, creatine kinase, metabolic panel and blood count may identify broader mitochondrial involvement but can be normal and are not diagnostic biomarkers.
  5. Cardiac/auditory assessment: considered when broader LHON-plus symptoms or family history suggest multisystem disease.

Genetic testing

  • Begin with targeted testing for common LHON variants plus MT-ND6 m.14459G>A when dystonia/basal-ganglia disease accompanies optic neuropathy.
  • If negative or atypical, perform complete mtDNA sequencing with heteroplasmy quantification and deletion analysis. Testing blood is convenient, but urine epithelial cells, buccal cells, or muscle may better detect low-level/tissue-variable heteroplasmy.
  • A nuclear optic-neuropathy/mitochondrial panel, WES or WGS is appropriate when mtDNA testing is negative or the phenotype is atypical. WGS can assess nuclear genes and mtDNA, but laboratories differ in mtDNA coverage and heteroplasmy validation.
  • CMA, karyotyping, FISH, and repeat-expansion tests have low first-line utility unless another diagnosis is suspected.

Differential diagnosis

Important alternatives are conventional LHON; OPA1-related dominant optic atrophy/“DOA-plus”; TIMM8A-related Mohr–Tranebjærg syndrome; WFS1 disease; OPA3/Costeff syndrome; ATP1A3 disease; mitochondrial Leigh/Leigh-like syndromes; Wilson disease; NBIA; dopa-responsive dystonia; multiple sclerosis/NMOSD/MOGAD; toxic-nutritional optic neuropathy; and compressive or inflammatory optic neuropathy. Early deafness plus X-linked inheritance favors TIMM8A disease, whereas maternal transmission plus an MT-ND6 variant favors LHOND.

There are no validated population or newborn-screening programs. Maternal-family cascade testing is appropriate after genetic counseling.

11. Outcome and prognosis

No subtype-specific survival curves, mortality rates, or life-expectancy estimates exist. The major burden is neurological disability rather than a demonstrated uniform reduction in survival. Visual loss is often severe and chronic; in the broader rare-mutation cohort, 75% of eyes reached ≤20/200 at their worst point. (cui2020clinicalfeaturesof pages 6-6)

Prognosis is heterogeneous and depends on visual severity, dystonia distribution, bulbar involvement, mobility, broader encephalopathy, mutant load, and environmental exposures. Neither a validated prognostic score nor a molecular biomarker exists for m.14459G>A LHOND. Complications include blindness, falls, contractures, pain, dysphagia/aspiration, loss of independence, anxiety and depression.

12. Treatment

Current strategy

There is no approved treatment specifically for m.14459G>A LHOND, and no controlled subtype-specific therapeutic trial was identified.

  • Optic neuropathy: early referral to a mitochondrial neuro-ophthalmology service; consider idebenone according to regional LHON authorization and specialist judgment. Evidence and approvals concern LHON broadly, especially common variants, not proven neurological benefit in m.14459G>A dystonia.
  • Dystonia: individualized oral therapy such as anticholinergic agents, baclofen, clonazepam, or other standard dystonia medicines; levodopa trial when dopa-responsive dystonia remains plausible; botulinum toxin for focal/segmental dystonia. Evidence is symptomatic and extrapolated.
  • Severe medication-refractory dystonia: globus-pallidus-internus deep-brain stimulation may be considered case by case, but no robust LHOND response rate is available.
  • Rehabilitation: low-vision services, orientation/mobility training, assistive technology, physical and occupational therapy, speech/swallowing therapy, nutrition, contracture prevention, and psychosocial support.

Suggested NCIt intervention concepts include genetic counseling, physical therapy, occupational therapy, speech therapy, low-vision rehabilitation, botulinum toxin therapy, and deep-brain stimulation; exact NCIt codes should be validated against the current release before database ingestion.

Experimental landscape

Current LHON trials overwhelmingly target MT-ND4 m.11778G>A, not MT-ND6 m.14459G>A. Registry examples include NCT07406854 (phase 3; 95 participants), NCT05293626 (phase 1/2; 12), NCT03406104 (phase 3 follow-up; 62), NCT03293524 (phase 3; 98), NCT03153293 (phase 2/3; 159), NCT02064569 (phase 1/2; 19), and NCT01267422 (9). An ND1 gene-therapy trial, NCT05820152, was terminated after enrolling 11. None establishes efficacy for LHOND. Mitochondrial base editing, heteroplasmy shifting, allotopic expression, and iPSC-derived retinal-ganglion-cell replacement remain investigational. (OpenTargets Search: Leber optic atrophy and dystonia)

13. Prevention

  • Primary prevention in carriers: avoid smoking, heavy alcohol use and avoidable mitochondrial toxins; maintain general health. Evidence is stronger for LHON overall than for LHOND. (berardo2020leberhereditaryoptic pages 1-3)
  • Secondary prevention: educate maternal relatives about early dyschromatopsia, central blur, involuntary posturing, gait change, and the need for urgent specialist review. Baseline and periodic ophthalmic/neurological examination may be reasonable, although no validated surveillance interval exists.
  • Tertiary prevention: early low-vision rehabilitation, dystonia treatment, fall/contracture prevention, swallowing assessment and mental-health support.
  • Reproductive counseling: discuss maternal transmission, heteroplasmy/bottleneck uncertainty, prenatal diagnosis, preimplantation genetic testing where technically appropriate, donor oocytes, adoption, and—where legal and available—mitochondrial-donation approaches. Prediction of phenotype from prenatal mutant load may remain uncertain.

Vaccination, antimicrobial prophylaxis, and infectious-disease public-health measures are not disease-specific interventions.

14. Other species and natural disease

No well-validated, naturally occurring veterinary equivalent of human m.14459G>A LHOND was identified. The orthologous mitochondrial ND6 gene is evolutionarily conserved across vertebrates, but naturally occurring optic-atrophy-plus-dystonia disease in a defined animal breed has not been established. There is no zoonotic potential or cross-species transmission because this is an inherited mitochondrial disorder.

15. Model organisms and experimental systems

The strongest disease-specific model is the transmitochondrial cybrid: patient mitochondria carrying m.14459G>A are placed into a standardized nuclear background. This assigned the respiratory complex-I defect to mutant mtDNA and is particularly valuable for separating mtDNA effects from nuclear modifiers. (yuwaiman2009inheritedmitochondrialoptic pages 10-10)

Other useful but predominantly general-LHON systems include patient fibroblasts, iPSCs, iPSC-derived retinal ganglion cells, retinal organoids, and engineered cells or animals carrying related complex-I mutations. These permit study of bioenergetics, ROS, apoptosis, heteroplasmy manipulation, neuroprotection and gene delivery. Their limitations are incomplete recapitulation of the human papillomacular bundle, mtDNA segregation, maternal-pedigree modifiers, and combined optic/basal-ganglia disease. No robust m.14459G>A animal model reproducing both human optic neuropathy and dystonia was verified.

Current understanding and evidence gaps

The best-supported model is that MT-ND6 m.14459G>A → complex-I dysfunction → deficient energetic reserve/redox stress → selective retinal-ganglion-cell and striatal neuronal injury → optic neuropathy plus dystonia. The cybrid evidence supports causality, but clinical prediction remains poor because homoplasmic relatives can differ dramatically. (yuwaiman2009inheritedmitochondrialoptic pages 10-10)

Priority research needs are an international genotype-defined registry; prospective OCT, MRI and movement-disorder natural history; tissue-level heteroplasmy studies; patient-derived striatal and retinal neuronal models; biomarkers of conversion; and trials that enroll rare non-ND4 LHON genotypes. Recent diagnostic work has improved broad hereditary-optic-neuropathy testing, but 2023–2024 therapeutic development remains concentrated on common LHON variants rather than LHOND.

Key references and supporting abstract language

  • Jun et al., 1996, Molecular and Cellular Biology, DOI: https://doi.org/10.1128/MCB.16.3.771. The title itself states that transmitochondrial cybrids “assign a complex I defect” to the ND6 nucleotide-14459 mutation causing LHON and dystonia; this is the pivotal functional study summarized in the retrieved review. (yuwaiman2009inheritedmitochondrialoptic pages 10-10)
  • Yu-Wai-Man et al., 2009, Journal of Medical Genetics, published March 2009, DOI: https://doi.org/10.1136/jmg.2007.054270. Abstract: “Additional genetic and environmental factors modulate the penetrance of LHON,” and “The selective vulnerability of retinal ganglion cells (RGCs) is a key pathological feature.” (yuwaiman2009inheritedmitochondrialoptic pages 10-10)
  • Cui et al., 2020, Journal of Neuro-Ophthalmology, published March 2020, DOI: https://doi.org/10.1097/WNO.0000000000000799. Abstract: “Patients with LHON and rare primary mutations have diverse clinical phenotypes,” and optic-nerve MRI signal “should not exclude LHON as the potential cause for optic neuropathy.” (cui2020clinicalfeaturesof pages 6-6)
  • Berardo et al., 2020, Journal of Neurology, DOI: https://doi.org/10.1007/s00415-019-09619-z. This case expands the LHON-plus spectrum through combined MT-ND4/MT-ND6 mutations and illustrates that optic neuropathy with dystonia is genetically heterogeneous. (berardo2020leberhereditaryoptic pages 1-3)
  • Rocatcher et al., 2023, Brain, DOI: https://doi.org/10.1093/brain/awac395. Abstract: “The positive diagnosis rate in individuals referred for Leber hereditary optic neuropathy testing was 18%,” with 92% of diagnosed cases carrying one of the three common mtDNA variants.

Evidence-quality note: primary functional evidence is strong for m.14459G>A causing complex-I dysfunction, but almost every clinical-domain estimate is limited by very small samples. General-LHON management, environmental, and trial findings have therefore been explicitly labeled as extrapolations rather than subtype-specific facts.

References

  1. (OpenTargets Search: Leber optic atrophy and dystonia): Open Targets Query (Leber optic atrophy and dystonia, 34 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (yuwaiman2009inheritedmitochondrialoptic pages 10-10): P Yu-Wai-Man, P G Griffiths, G Hudson, and P F Chinnery. Inherited mitochondrial optic neuropathies. Journal of Medical Genetics, 46:145-158, Nov 2009. URL: https://doi.org/10.1136/jmg.2007.054270, doi:10.1136/jmg.2007.054270. This article has 568 citations and is from a domain leading peer-reviewed journal.

  3. (cui2020clinicalfeaturesof pages 6-6): Shilei Cui, Ling Yang, Hanqiu Jiang, Jingting Peng, Jun Shang, Jiawei Wang, and Xiaojun Zhang. Clinical features of chinese sporadic leber hereditary optic neuropathy caused by rare primary mtdna mutations. Journal of Neuro-Ophthalmology, 40:30-36, Mar 2020. URL: https://doi.org/10.1097/wno.0000000000000799, doi:10.1097/wno.0000000000000799. This article has 24 citations and is from a peer-reviewed journal.

  4. (berardo2020leberhereditaryoptic pages 1-3): Andres Berardo, Valentina Emmanuele, Wendy Vargas, Kurenai Tanji, Ali Naini, and Michio Hirano. Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in mt-nd4 and mt-nd6. Journal of Neurology, 267:823-829, Nov 2020. URL: https://doi.org/10.1007/s00415-019-09619-z, doi:10.1007/s00415-019-09619-z. This article has 30 citations and is from a domain leading peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 7
Resolved 7
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 7
On topic 4
Off topic 0

All extracted references resolved successfully.